Check for updates

OPEN ACCESS

EDITED BY Xianwei Che, Hangzhou Normal University, China

REVIEWED BY Weiwei Peng, Shenzhen University, China Shyam Sundar Arumugham, National Institute of Mental Health and Neurosciences (NIMHANS), India

*CORRESPONDENCE Hong Li ⊠ 18734558363@163.com

RECEIVED 02 July 2024 ACCEPTED 28 August 2024 PUBLISHED 16 September 2024

CITATION

Wang J, Yao X, Ji Y and Li H (2024) Cognitive potency and safety of tDCS treatment for major depressive disorder: a systematic review and meta-analysis. *Front. Hum. Neurosci.* 18:1458295.

doi: 10.3389/fnhum.2024.1458295

COPYRIGHT

© 2024 Wang, Yao, Ji and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Cognitive potency and safety of tDCS treatment for major depressive disorder: a systematic review and meta-analysis

Junjie Wang^{1,2}, Xinru Yao³, Yuqi Ji^{4,5} and Hong Li^{4,5}*

¹School of Psychology, Capital Normal University, Beijing, China, ²Beijing Key Laboratory of Learning and Cognition, School of Psychology, Capital Normal University, Beijing, China, ³Department of Psychology, University of Tuebingen, Tübingen, Germany, ⁴Department of Psychiatry, The First Hospital of Shanxi Medical University, Taiyuan, China, ⁵Shanxi Key Laboratory of Artificial Intelligence Assisted Diagnosis and Treatment for Mental Disorder, The First Hospital of Shanxi Medical University, Taiyuan, China

Background: The benefits of transcranial direct current stimulation (tDCS) for patients with major depression disorders are well-established, however, there is a notable research gap concerning its comprehensive effects on both depressive symptoms and cognitive functions. Existing research is inconclusive regarding the cognitive enhancement effects of tDCS specifically in MDD patients. The present study aims to fill this knowledge gap by scrutinizing the most updated evidence on the effectiveness of tDCS in anti-depressive treatment and its influence on cognitive function.

Methods: A systematic review was performed from the first date available in PubMed, EMBASE, Cochrane Library, and additional sources published in English from 1 January 2001 to 31 May 2023. We examined cognitive outcomes from randomized, sham-controlled trials of tDCS treatment for major depression. The evaluation process strictly followed the Cochrane bias risk assessment tool into the literature, and meta-analysis was performed according to the Cochrane System Reviewer's Manual.

Results: In this quantitative synthesis, we incorporated data from a total of 371 patients across 12 studies. Results showed significant benefits following active tDCS compared to sham for the antidepressant effect [SMD: -0.77 (-1.44, -0.11)]. Furthermore, active relative to sham tDCS treatment was associated with increased performance gains on a measure of verbal memory [SMD: 0.30 (-0.02, 0.62)]. These results did not indicate any cognitive enhancement after active tDCS relative to sham for global cognitive function, whereas there was a noticeable trend toward statistical significance specifically in the effect of verbal memory.

Conclusions: Our study offers crucial evidence-based medical support for tDCS in antidepressant and dimension-specific cognitive benefits. Further well-designed, large-scale randomized sham-controlled trials are warranted to further validate these findings.

Systematic Review Registration: https://inplasy.com/, identifier: INPLASY2023 60008.

KEYWORDS

transcranial direct current stimulation, depression, treatment, cognition, meta-analysis

1 Introduction

Depression, as a neuropsychiatric condition, frequently coexists with chronic pain, a multifaceted disorder characterized by a constellation of sensory, cognitive, and affective symptoms (Chopra and Arora, 2014). Indeed, clinical research has underscored the significant comorbidity between pain and depression, with a notable study revealing a prevalence of 30% comorbidity between the two conditions, wherein each condition reciprocally exacerbates the other (Kroenke et al., 2011; Miller and Cano, 2009). Furthermore, prior research has revealed that patients enduring cognitive impairment often encounter unfavorable clinical outcomes (Hale et al., 2020; Ismail et al., 2017). Within this population, major depression disorder (MDD) is linked to notable decrements in executive function, working memory, and attention (Keefe et al., 2014; Wagner et al., 2012), potentially resulting in increased healthcare utilization and costs (Egede, 2007), as well as decreased adherence to medical treatments (DiMatteo et al., 2000). Thus, successfully treating depression could significantly enhance cognitive functions and improve prognosis in these patients. In recent years, psychiatric centers and health care services have increasingly emphasized the integration of physiotherapy for cognitive remediation, aiming to promote recovery and expand physical therapy for coping with mental illness (Douglas et al., 2022; Poppe et al., 2021).

Transcranial direct current stimulation (tDCS) has been explored as a physical intervention that may help alleviate depression symptoms and enhance cognitive functions for patients with MDD (Martin et al., 2018). The last decades saw an important growth of demand for this treatment, leading to a greater need for more efficient and safe methods of delivery. On the other hand, tDCS may be hampered by the therapeutic difficulties common to all forms of physical therapy, e.g., optimal parameters and treatment duration. Previously, tDCS involved applying small direct current to the brain through two electrodes placed on the scalp. In modern clinical trials for depression, tDCS is typically administered for 10-30 min per session, with a current intensity ranging from 1 to 2.5mA. This treatment is often administered once or twice daily over several weeks (Brunoni et al., 2016). Typically, these trials involve placing an anode or excitatory stimulus on an individual's left dorsolateral prefrontal cortex (DLPFC), while the cathode or reference electrode is positioned frontally on the contralateral side of the brain. Notably, the DLPFC is considered as a crucial hub within the "cognitive control" network that is often dysfunctional in depression (Williams, 2017). Current evidence suggests that tDCS possesses potent antidepressant properties. However, its effectiveness in enhancing cognitive function in patients with MDD remains inconclusive (Brunoni et al., 2017; Lefaucheur et al., 2017).

Cognitive dysfunction is a prominent symptom of MDD (Culpepper et al., 2017), manifesting as moderate impairments in executive function, memory, and attention in depressed patients (Rock et al., 2014). In patients with comorbid depression and cognitive dysfunction, previous randomized controlled trials (RCTs) have indicated that psychotherapy can be an effective treatment option (Miguel et al., 2023). Notably, some studies have observed cognitive benefits in patients with major depression following a series of tDCS sessions. However, a meta-analysis

conducted by Martin et al. (2018) found no significant cognitive enhancement following active tDCS compared to sham for 12 cognitive outcomes across 478 MDD patients. While more clinical trials on cognitive functions in depressed patients have been published in recent years, potentially altering previous findings, the exact extent of tDCS effects on depression, cognitive-related outcomes (such as verbal memory and executive function), and adverse events (like pain and headache) remains uncertain. There is ongoing debate about which specific cognitive dimensions are most affected by tDCS. Additionally, current clinical research on tDCS often involves small sample sizes or even case reports, leading to inconsistencies in overall results. Finally, there is a scarcity of systematic reviews and meta-analyses assessing the effectiveness of tDCS in improving cognitive function in depression. Consequently, there is a pressing need for a comprehensive assessment of the evidence regarding tDCS's efficacy and its impact on cognitive function.

Thus, we aimed to determine whether a tDCS treatment course for major depression induces cognitive enhancement. We focused specifically on RCTs that evaluated cognitive functions in MDD patients receiving tDCS treatment. This targeted approach was taken given the increasing clinical importance of addressing cognitive impairments in depression and the need for evidencebased information on the cognitive effects of tDCS. However, it is acknowledged that this decision limited the sample scope and may have introduced bias by excluding studies that solely assessed the antidepressant efficacy of tDCS without considering cognitive outcomes. Despite this limitation, the aim was to provide a focused investigation into the potential cognitive benefits of tDCS for MDD patients. Current studies on tDCS's role in enhancing cognitive functions in depression yield conflicting results. This inconsistency underscores the pressing need for a comprehensive meta-analysis to systematically assess tDCS's therapeutic effectiveness. These analyses will clarify the overall impact of tDCS on cognitive functions in depressed patients, identify potential moderators of treatment efficacy, and guide future research and clinical applications.

In the current study, cognitive measures represented key cognitive domains including global cognitive function, verbal memory, executive function, and working memory. Through these efforts, we endeavor to deepen our understanding of the effectiveness of tDCS in anti-depressive treatment and its impact on cognitive function. Of note, we focused exclusively on MDD patients due to their significant cognitive impairments affecting daily life. Subthreshold depression patients have less severe symptoms and potentially lesser cognitive issues. To ensure consistency and statistical power, we included only MDD patients meeting diagnostic criteria. This understanding would serve as a solid foundation for further promoting the clinical application of tDCS.

2 Methods

2.1 Protocol registration

A systematic literature review and meta-analysis was conducted followed INPLASY (https://inplasy.com/) procedures and focused

on the tDCS treatment for MDD patients with cognitive dysfunction. This review protocol was pre-registered in INPLASY (INPLASY202360008) and adhered to the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) reporting guideline (Moher et al., 2009).

2.2 Search strategy

We performed a systematic literature search in Pubmed, Embase, Web of Science, and Cochrane library, using both keywords and MeSH terms in the database ranged from 1 January 2008 to 31 May 2023. For additional references, we also searched the reference lists from the selected papers and other systematic meta reviews. The search strings for literature reviews included terms "depression," "depressive disorder," "dysthymi*," "affective disorder," "mood disorder," "mood disorders," "depression*," "depressive*," "transcranial direct current stimulation," and "tDCS." Two researchers reviewed and screened all records, and if there were disagreements, then they were resolved by consensus.

2.3 Eligibility criteria

For this systematic review and meta-analysis, we included: (1) subjects: patients with a disease diagnosis that met the Diagnostic and Statistical Manual of Mental Disorders (DSM) diagnostic criteria for depressive episodes to ensure homogeneity across studies; (2) age \geq 18 years; (3) interventions: tDCS group and sham tDCS; (4) randomized sham-controlled trials (RCTs), which provide the highest level of evidence and minimize biases; (5) standardized neuropsychological test was performed at baseline and after treatment, and (6) peer-reviewed manuscripts in English.

Exclusion criteria: (1) missing full text or original data (e.g., meeting abstracts); (2) high-risk bias: studies were assessed using the Cochrane Risk of Bias Assessment Tool and excluded if four or more of them were high risk; (3) repeatedly published literature; (4) animal experiments, review literature, case studies were excluded to maintain the robustness and validity of our results; (5) unclear description of intervention methods, e.g., only including the tDCS group without a control group; and (6) lack of a sham-control group as well as neuropsychological test.

2.4 Data extraction

The retrieved documents were imported into EndnoteX9. Two researchers independently extracted data from qualified studies regarding author, publication year, sample size, average age, clinical characteristics, tDCS parameters, and neuropsychological performance. We extracted test score with standard deviation (SD), sample size, and *P*-values for effective size (ES) generation.

The primary outcomes included total scores on the depression scale and ratings across neuropsychological tests dimensions, such as global cognitive function, verbal memory, attention, executive function, and other cognitive dimensions. Secondary outcome refers to adverse events in this study.

2.5 Quality assessment

Study data were extracted by two independent reviewers, using consensus discussions for disagreements, and final data verifications conducted by the study statistician. The reviewers separately evaluated eligible studies using the Cochrane Collaboration Risk of Bias (RoB) tool: (a) random sequence generation; (b) allocation concealment; (c) blinding of participants and personnel; (d) blinding of outcome assessment; (e) Incomplete outcome data; (f) Selective reporting; (g) other bias, e.g., quality control of treatment procedures, adverse events (Higgins et al., 2011). The level of risk of bias is expressed as "low risk" and "high risk", respectively, and "unclear" is used when the article has insufficient information.

2.6 Data analysis

Review Manager 5.3 software was used to assess the risk bias of included qualified studies. The effect size of heterogeneity of the studies was assessed by I^2 statistic and *P*-values: $I^2 > 50\%$ or P < 0.05 indicates high heterogeneity, and the random-effects model is used for meta-analysis; $I^2 \leq 50\%$ or P > 0.1, indicating that the research is homogeneous, then the fixed effects model is used. Meta-analysis was carried out according to the Cochrane System Reviewer's Manual. Observation indicators included in this study are continuous variables, since the scores of each test are continuous variables and the scale version used in each document is different, the standardized mean difference (SMD) is selected as the combined effect size.

3 Results

3.1 Study selection and study characteristics

Initial screenings identified 14,958 records from Web of Science, PubMed, Embase, and Cochrane Library databases. After removing duplicate publications, 11,231 articles were obtained. Forty-six systematic reviews and meta-analysis articles, 223 irrelevant article, and 1 animal research were excluded, 56 articles were obtained. In total, articles not meeting the selection criteria were excluded after reading the titles and abstracts, resulting in the exclusion of 270 articles. These records were screened, which led to full-text scrutiny of 56 articles. After carefully reading the 56 articles, 42 articles without a control group, four outcome indicators do not meet the inclusion criteria. Finally, 12 articles were included for meta-analysis, including a total of 371 subjects (Table 1). The process of literature screening is shown in Figure 1.


3.2 Basic characteristics and risk bias assessment of included literature

The 12 articles finally included were all RCTs experiments. Due to the particularity of the intervention treatment, the design and implementation of random grouping may face certain challenges.

TABLE 1 Characteristics of randomized clinical trials included in the meta-analysis.

References	Cli	nical cha	aracteristics		Dep	ression c	haracteristic	S			tDCS t	reatment			Cognitive performance
	N	% female	Age (mean \pm SD)	Dx	TRD	Primary scale	Previous medication use	Treatment strategy	tDCS device	Anode	Cathode	Current, electrode size	Session duration (min/d)	Sessions	Test
Bennabi et al. (2015)	24	64.4	60.1 ± 13.7	MDD	Y	HDRS-21	Stable doses	Augmentation	NeuroConn	F3	SO-R	2 mA; 35 cm ²	30	10	TMT, MMSE, Isaacs Set Test, MIS, Picture naming test
Loo et al. (2010)	40	55	47.3 ± 12.2	MDD	N	MADRS	Stable doses	Add-on	NeuroConn	PF3	F8	1 mA; 35 cm ²	20	5	RAVLT, TMT, Digit Span, COWAT, SDMT
Loo et al. (2012)	64	47	47.8 ± 12.5	MDD/ BD	Ν	MADRS	Stable doses	Add-on	NeuroConn	PF3	F8	2 mA; 35 cm ²	20	15	RAVLT, Digit Span, Letter-number sequencing, COWAT, Stroop
Mayur et al. (2018)	16	37.5	44.9 ± 14.7	MDD	Y	MADRS	Not allowed	Augmentation	NeuroConn	F3	F4	2 mA; 25 cm ²	30	10	MOCA, Visual memory score
Nord et al. (2019)	39	51.3	33.3 ± 10.6	MDD	Y	HDRS	Not allowed	Augmentation	NeuroConn	F3	Deltoid	1 mA; 35 cm ²	20	8	back
Palm et al. (2012)	22	64	57 ± 12	MDD	Y	HDRS-24	Stable doses	Add-on	NeuroConn	F3	SO-R	1.5 mA; 35 cm ²	20	10	Verbal Learning Memory Test, Regensburg Word Fluency Test, Letter Number Sequencing Task of the Wechsler Adult Intelligence Scale
Salehinejad et al. (2015)	30	56.6	28.3 ± 28.2	MDD	NI	HDRS	Not allowed	Monotherapy	TCT Research Limited	F3	F4	2 mA; 35 cm ²	20	10	Delayed Matching to Sample, Pattern Recognition Memory
Salehinejad et al. (2017)	24	62.5	26.1 ± 5.8	MDD	NI	BDI	Not allowed	Monotherapy	Activa Dose Ionto- phoresis	F3	F4	2 mA; 35 cm ²	20	10	Paired Associates Learning, Spatial Recognition Memory, Rapid Visual Information Processing; Choice Reaction Time
Moreno et al. (2020)	64	94	44.61 (11.82)	MDD	N	HDRS-17	Wash-out	Monotherapy	Soterix	F3	F4	2 mA;	30	22	MOCA, TMT, Digit span, SDMT, Verbal-Fluency, Processing Speed, Working Memory
Kumar et al. (2020)	18	72	66.33 (5.83)	MDD	Ν	MADRS	N/I	Add-on	Magstim®	F3/F4	Iz	1 mA; 25 cm ²	30	10	N-back, Boston Naming Test, Brief Visuospatial Memory Test, Clock Drawing Test, Continuous Performance Test, California Verbal Learning Test, Digit Symbol Subtest, Stroop
Nejati et al. (2022)	20	100	30.35 ± 6.83	MDD	N	BDI	Wash-out	Add-on/ Monotherapy	ActivaTek Inc.	F3, Fp2	Fp2, F3	1.5 mA; 25 cm ²	20	3	Go/No-Go, Stroop, 1-Back
Figeys et al. (2022)	10	40	77.10 ± 6.98	Depression, Anxiety	N	GDS, GDA	NI	NI	HDCStim	F3	supraorbital	1.5 mA; 35 cm ²	20	10-14	SDMT, TMT, Digit span, Stroop

MDD, major depression disorder; BD, bipolar disorder; HDRS, Hamilton Depression Rating Scale; MADRS, Montgomery-Asberg Depression Rating Scale; BDI, Beck Depression Inventory; GDS, Geriatric Depression Scale; GDA, Geriatric Anxiety Inventory; TMT, Trail Making Test; RAVLT, Rey Auditory Visual Learning Test; COWAT, Controlled Oral Word Association Test; SDMT, Symbol Digit Modalities Test; MOCA, Montreal Cognitive Assessment; MMSE, Mini Mental State Examination; Y, yes; N, no; NI, not informed.



All included articles reported attrition of patients, with relatively complete and test results, and no specific documentation describing concealment distribution. The basic characteristics of the literature are shown in Table 1, and the risk assessment of risk bias is shown in Figure 2.

effects were detected [g = 0.30, 95% CI (-0.02, 0.62); Figure 4B] when pooling four trials that specifically reported verbal memory deficits. This result indicates a trend toward improvement in verbal memory with active tDCS treatment compared to sham.

3.3 The efficacy of antidepressant treatment of tDCS and its impact on cognition

3.3.1 Overall effects of tDCS treatments for depression

We evaluated the effectiveness of tDCS for improving depressive symptoms using endpoint depression scores, including a total of seven studies involving 191 patients. Meta-analysis results showed that active tDCS was more effective in antidepressant than in the sham group [g = -0.77, 95% CI (-1.44, -0.11); Figure 3].

3.3.2 Results of global cognitive function and verbal memory measures


Included studies used global cognitive function to assess cognitive improvements in tDCS treatment for depression patients. The pooled effect size at post-test across 3 tDCS studies was not significant, with g = -0.01, 95% CI (-0.36, 0.33); Figure 4A. Heterogeneity was low, $I^2 = 0\%$. In addition, we used RAVLT/VLMT to assess verbal memory performance for tDCS treatment with MDD patients. Finally, marginal significant

3.3.3 Multi-aspects outcomes of cognitive function measures

Neuropsychological test, i.e., N-back, Stroop, and TMT-B was used to evaluate the effect of MDD patients' executive function. No significant effect sizes were observed in any of the examined specific outcomes: for N-back [g = 0.11, 95% CI (-0.56, 0.79); Figure 5], Stroop [g = 0.23, 95% CI (-0.48, 0.94); Figure 3], and TMT-B [g = 0.33, 95% CI (-0.18, 0.84); Figure 5].

Subgroup analysis of attention outcomes in MDD patients indicated that tDCS treatment was not better than that after sham group. Specifically, no significant effects were found when pooling 4 trials that consistently reported digit span, including forward [g = -0.19, 95% CI (-0.45, 0.08); Figure 5] and backward [g = -0.06, 95% CI (-0.40, 0.28); Figure 5]. And heterogeneity was low, with $I^2 = 0\%$ and $I^2 = 30\%$. TMT-A was reported in four trials on patients with MDD. The pooled estimate demonstrated no significant effects at post-treatment [g = 0.61, 95% CI (-0.44, 1.66); Figure 5], whereas with high heterogeneity $(I^2 = 87\%)$.

Three studies used neuropsychological evaluation to evaluate the efficacy of SDMT in MDD patients, totally 93 patients were included. Results found that there were no significant differences in SDMT between the two groups [g = -0.04, 95% CI (-0.61, 0.53); Figure 5]. At the same time, two studies used neuropsychological



evaluation to evaluate the efficacy of working memory in MDD patients, totally including 76 patients. Results found that there were no significant differences in working memory between the two groups [g = 0.40, 95% CI (-0.67, 1.47); Figure 5]. Of note, N-back is the primary tool for assessing working memory capacity and attention control, whereas the other two working memory tests mentioned in the literature mainly evaluate short-term learning and memory. Thus, we analyzed these aspects distinctly in our final analysis.

3.4 Adverse events

All-cause adverse events were reported in 3 studies on pain, burning/heating sensation at anode and/or cathode site, headache etc. Pooling 3 trials that reported at least one adverse event of the conditions, we obtained a non-significant difference between the two groups [OR = 1.19, 95% CI (0.49, 2.90); Figure 6].

4 Discussion

This study presents a systematic review and meta-analysis of the clinical efficacy of tDCS in antidepressant treatment and its impact on cognitive function. It is worth noting that there were two studies on the current work topic (Martin et al., 2018), both of which provide valuable insights into the potential benefits of tDCS in enhancing cognitive function in patients with depression, and they are not without limitations. Firstly, the study by Martin et al., despite conducting a meta-analysis of individual patient data, had a relatively limited sample size and number of included studies, potentially affecting the generalizability and statistical power of the findings. Additionally, its examination of individualized differences and long-term effects was inadequate, limiting our understanding of response patterns across patient groups and the durability of treatment benefits. On the other hand, the systematic review by Jin et al., while comprehensive in scope, lacked a meta-analysis to provide quantitative effect estimates. This reliance on narrative descriptions limited the robustness of its conclusions. Furthermore, it lacked an in-depth exploration of the underlying mechanisms and offered only general suggestions for future research directions.

To address these limitations, by compiling data from twelve randomized, sham-controlled studies, we quantitatively analyzed cognitive performance across key cognitive domains, including global cognitive functioning, verbal memory, executive functioning, attention and working memory. For antidepressant efficacy, meta-analysis results showed that active tDCS was more effective than in the sham group for MDD patients, demonstrated that tDCS has a good antidepressant effect. However, our study did not demonstrate significant differences in the effects of global cognitive function for a treatment course of active tDCS compared to sham treatment in MDD patients, whereas there was a marginal significant difference in the effect of verbal memory, which underscores the potential for tDCS to enhance verbal memory in patients with MDD, and future studies with larger sample sizes or more targeted tDCS protocols may help clarify this effect. Additionally, the use of specific neuropsychological tests designed to detect subtle changes in verbal memory performance may aid in detecting statistically significant effects. Furthermore, we performed subgroup analyses to explore the effects of tDCS on eight cognitive function outcomes (e.g., attention, working memory). These analyses did not reveal any beneficial effects of active tDCS compared to sham treatment across the examined dimensionspecific cognitive measures. In summary, our study provides an important evidence-based medical support for the antidepressant efficacy of tDCS and its dimension-specific cognitive benefits, contributing to a deeper understanding of its clinical applications.

Our study demonstrated that tDCS has a good antidepressant effect, which was consistent with the initial findings of Salehinejad

	1	tDCS		C	ontrol			Std. Mean Difference	Std. Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
Kumar 2020	3.17	4.38	18	3.29	3.15	15	15.3%	-0.03 [-0.72, 0.66]	+
Loo 2010	15.43	6.69	19	13.5	5.45	15	15.3%	0.31 [-0.38, 0.99]	
Loo 2012	3.7	0.14	31	3.93	0.14	29	16.0%	-1.62 [-2.21, -1.03]	-
Mayur 2018	6.45	2.02	8	14.65	3.76	8	10.0%	-2.57 [-3.99, -1.15]	
Nord 2019	6.68	6.49	20	9.3	6.82	19	15.7%	-0.39 [-1.02, 0.25]	
Palm 2012	23.1	5.2	11	26.5	11.7	11	14.1%	-0.36 [-1.21, 0.48]	
Salehinejad 2017	12.75	3.36	12	16.83	2.26	12	13.6%	-1.38 [-2.28, -0.47]	-
Total (95% CI)			119			109	100.0%	-0.77 [-1.44, -0.11]	•
Heterogeneity: Tau ² =	= 0.63; C	$hi^2 = 3$	31.75.	df = 6 (P < 0.0	0001);	$ ^2 = 81\%$		
Test for overall effect	: Z = 2.2	8 (P =	0.02)						-10 -5 0 5 10 Favours [control] Favours [tDCS]

Forest plot of the efficacy of tDCS in the treatment of depression.

A MOCA/MMSE

		tDCS		Co	ontrol		S	td. Mean Difference	Std. Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	IV, Fixed, 95% CI
Bennabi 2014	25.3	2.7	10	26.4	2.86	5	10.2%	-0.38 [-1.46, 0.71]	
Mayur 2018	25	4.78	8	26.29	4.88	7	11.6%	-0.25 [-1.27, 0.77]	
Moreno 2019	25.9	2.94	64	25.69	3.27	41	78.2%	0.07 [-0.32, 0.46]	+
Total (95% CI)			82			53	100.0%	-0.01 [-0.36, 0.33]	•
Heterogeneity: Chi ² =	0.80, d	f = 2 (f	P = 0.6	7); $I^2 =$	0%			-	
Test for overall effect									
			,						Favours [tDCS] Favours [control]
RAVLT/VLMT									
		tDCS		C	ontrol			Std. Mean Difference	Std. Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD) Tota	Weight	IV, Fixed, 95% CI	IV, Fixed, 95% CI
stan) et sangteap			10000		10.	15	21 20/		
Kumar 2020	56.28	14.49	18	55.53	12.4	1 12	21.3%	0.05 [-0.63, 0.74]	
		14.49 10.59		55.53 51.76	9.41	1.1.1.1		0.05 [-0.63, 0.74] 0.22 [-0.46, 0.90]	
Kumar 2020	54.05		19	51.76		15	21.7%		
Kumar 2020 Loo 2010 Loo 2012	54.05	10.59 12.52	19 31	51.76 52.4	9.41	15	21.7% 38.6%	0.22 [-0.46, 0.90]	
Kumar 2020 Loo 2010	54.05 56	10.59 12.52	19 31	51.76 52.4	9.41 10.15	15 29 15	21.7% 38.6%	0.22 [-0.46, 0.90] 0.31 [-0.20, 0.82]	
Kumar 2020 Loo 2010 Loo 2012 Salehinejad 2015 Total (95% CI)	54.05 56 66.43	10.59 12.52 12.04	19 31 15 83	51.76 52.4 57.8	9.41 10.15 13.71	15 29 15	21.7% 38.6% 18.4%	0.22 [-0.46, 0.90] 0.31 [-0.20, 0.82] 0.65 [-0.09, 1.39]	
Kumar 2020 Loo 2010 Loo 2012 Salehinejad 2015	54.05 56 66.43 1.42, df	10.59 12.52 12.04 = 3 (P	19 31 15 83 = 0.70	51.76 52.4 57.8	9.41 10.15 13.71	15 29 15	21.7% 38.6% 18.4%	0.22 [-0.46, 0.90] 0.31 [-0.20, 0.82] 0.65 [-0.09, 1.39]	-4 -2 0 2 4 Favours [control] Favours [tDCS]

et al. (2017) and Palm et al. (2012). Interestingly, this finding was driven largely by the Salehinejad et al. (2017) study where patients similarly received monotherapy treatment, who attributed the significant improvement in mood scores for depression to an ameliorate of patient's cognitive control deficits. However, this conclusion diverges slightly from the findings of Loo et al. (2018), who conducted a comprehensive international trial on tDCS for depression and demonstrated a null result. One potential explanation for this difference could be the relatively small sample size of our study. Additionally, based on our meta-analysis results, studies that followed a more standard daily or near-daily dosing schedule were included, and confounding variables such as drug dosage may have influenced the consistency of the findings across these studies. Given the ameliorating effect of tDCS on negative mood in MDD (Wang et al., 2022; Aust et al., 2022), electrical stimulation could be recognized as a complementary approach to maximize the therapeutic effect of psychological interventions on MDD.

We found no significant differences in the impact on global cognitive function between active tDCS and sham treatment courses. Notably, this result should be considered with caution, since the number of trials was small, and these analyses are likely underpowered. Our results align with a previous metaanalysis of seven randomized sham-controlled trials in adults with MDD, which also failed to show any cognitive benefits from tDCS (Martin et al., 2018). Indeed, some studies have shown positive effects of tDCS on cognition in patients with active MDD, these improvements may be attributed to mood enhancement (Gogler et al., 2017; Moreno et al., 2015; Wolkenstein and Plewnia, 2013). Nevertheless, our findings identified that patients who received active tDCS relative to those who received sham tDCS showed increased performance gains following the treatment course on the verbal memory measures. Studies in patients with cognitive disorders have shown the benefits of tDCS combined with cognitive tasks on visual memory, attention and executive function (Boggio et al., 2009; Nelson et al., 2014; Chen et al., 2022; Simko et al., 2021).

umar 2020 3.06 0.61 18 2.22 0.55 15 3.44 0.27 1-042.05] sing 2021 2.76 0.13 2.26 1.13 0.29 0.37, $M = 0.37, M = 0.42, 0.64, 0.25$ large 2022 1.26 0.13 2.26 1.23 0.29 0.00; $\mu^2 = 038$ therefore overall effect: $2 = 0.32$ ($\mu = 0.75$) 1.12 Stroop iggs 2022 3.46 0.53 10 0.665 3.96 11 2.268 0.666, 0.291 iggs 2021 1.06 0.11 2.01 1.3 0.15 20 3.77, 0.511 0.80, 0.57] or 2012 2.64 1.85 33 22.7 1.89 31 4.33 0.90 (0.38, 1.41] setterogenety: Tau ² = 0.41; Ch ² = 3.73 (d = 3.9 = 0.003); $\mu^2 = 788$ test for overall effect: $2 = 0.32$ ($\mu = 0.75$) 1.13 Stroop iggs 2021 3.06 1.1 2.21 11 5 2.21% 0.00 (-1.07, 1.07] iggs 2021 3.06 1.1 2.23 (d = 3.9 = 0.003); $\mu^2 = 788$ test for overall effect: $2 = 0.32$ ($\mu = 0.72$) 1.13 Stroop iggs 2021 3.06 1.1 4.10 4.0.31 4.14 8.10 2.066 0.064 (-1.027, 1.07] iggs 2021 3.06 1.1 9.61 0.031 1.02 1.96 2.033 1.14 Stroop iggs 2022 1.306 1.14 9.74 10 6.63 7 24.07 11 2.248 0.041 (-1.04, 0.03) itercogenety: Tau ² = 0.97; Ch ⁴ = 2.73, df = 3.9 e 0.0031; $\mu^2 = 878$ test for overall effect: $2 = 1.58$ ($\mu = 0.27$) 1.14 Stroop iggs 2021 1.306 1.45.74 11 8 65.3 1.2.74 (d = 3.9 e 0.0031; $\mu^2 = 878$ test for overall effect: $2 = 1.58$ ($\mu = 0.27$) 1.15 Digt Span (Groward) iggs 2021 1.306 1.45.74 11 8 6.50 1.3 3.44 (d = 0.26) (-1.16, 1.19, 0.96] iggs 2021 1.306 4.46 4.73 1.9 e 0.11; $\mu^2 = 508$ test for overall effect: $2 = 1.38$ ($\mu = 0.02$); $\mu^2 = 308$ test for overall effect: $2 = 1.38$ ($\mu = 0.02$); $\mu^2 = 308$ test for overall effect: $2 = -1.38$ ($\mu = 0.02$); $\mu^2 = 308$ test for overall effect: $2 = -3.34$ ($\mu = 0.02$); $\mu^2 = 308$ test for overall effect: $2 = -3.34$ ($\mu = 0.02$); $\mu^2 = 308$ test for overall effect: $2 = -3.34$ ($\mu = 0.02$); $\mu^2 = 308$ test for overall effect: $2 = -3.34$ ($\mu = 0.02$); $\mu^2 = 308$ test for overall effect: $2 = -3.34$ ($\mu = 2.0 = 0.00$); $\mu^2 = 388$ to for overall effect: $2 = -0.34$ ($\mu = 0.02$); $\mu^2 = 308$ test for overall effect: $2 = -0.34$ ($\mu = 0.02$); $\mu^2 = 308$ test for overall effect: $2 = -0.34$	Study or Subgroup	t Mean	DCS SD	Total	C Mean	ontrol SD	Total	Weight	Std. Mean Difference IV, Random, 95% CI	Std. Mean Difference IV, Random, 95% CI
Equil 2022 1.07 0.13 20 1.13 0.09 20 3.7% -0.33 [-1.6.0.1] 0.041 20 4.7% 0.03 [-0.61 -0.61, 0.13] 0.041 -0.65, 0.79] 0.01 [-0.56, 0.79] 0.02 [-0.56, 0.79] 0.02 [-0.56, 0.79] 0.02 [-0.56, 0.79] 0.02 [-0.56, 0.79] 0.02 [-0.56, 0.79] 0.02 [-0.56, 0.79] 0.02 [-0.56, 0.79] 0.02 [-0.56, 0.79] 0.02 [-0.56, 0.79] 0.02 [-0.56, 0.79] 0.02 [-0.56, 0.79] 0.02 [-0.56, 0.79] 0.02 [-0.56, 0.79] 0.02 [-0.56, 0.79] 0.02 [-0.56, 0.79] 0.02 [-0.56, 0.79] 0.02 [-0.56, 0.57] 0.21 [-0.56, 0.21] 0.02 [-0.56, 0.57] 0.21 [-0.56, 0.21] 0.02 [-0.56, 0.21] 0.02 [-0.56, 0.21] 0.02 [-0.56, 0.21] 0.02 [-0.56, 0.21] 0.02 [-0.56, 0.21] 0.02 [-0.56, 0.21] 0.02 [-0.56, 0.21] 0.02 [-0.56, 0.21] 0.02 [-0.56, 0.21] 0.02 [-0.56, 0.21] 0.02 [-0.56, 0.21] 0.02 [-0.56, 0.21] 0.02 [-0.56, 0.21] 0.02 [-0.56, 0.21] 0.02 [-0.56, 0.21] 0.02 [-0.56, 0.21] 0.02 [-0.56, 0.21] 0.02 [-0.56, 0.22] 0.05 [-0.57, 0.22] 0.05 [-0.57, 0.22] 0.05 [-0.57, 0.22] 0.05 [-0.57, 0.22] 0.05 [-0.57, 0.22] 0.05 [-0.57, 0.22] 0.05 [-0.56, 0.02] 0.03 [-0.18, 0.84] 0.05 [-0.57, 0.22] 0.05 [-0.56, 0.02] 0.03 [-0.18, 0.84] 0.05 [-0.57, 0.22] 0.05 [-0.56, 0.02] 0.03 [-0.18, 0.84] 0.05 [-0.57, 0.22] 0.05 [-0.56, 0.02] 0.03 [-0.18, 0.84] 0.05 [-0.57, 0.22] 0.05 [-0.56, 0.02] 0.05 [-0.56, 0.02] 0.05 [-0.56, 0.02] 0.05 [-0.57, 0.22] 0.05 [-0.56, 0.02] 0.05 [-0.57, 0.22] 0.05 [-0.56, 0.02] 0.05 [-0.57, 0.22] 0.05 [-0.56, 0.02] 0.05 [-0.57, 0.22] 0.05 [-0.56, 0.02] 0.05 [-0.57, 0.22] 0.05 [-0.56, 0.02] 0.05 [-0.57, 0.22] 0.05 [-0.56, 0.02] 0.05 [-0.57, 0.22] 0.05 [-0.56, 0.02] 0.05 [-0.57, 0.22] 0.05 [-0.56, 0.02] 0.05 [-0.57, 0.22] 0.05 [-0.56, 0.02] 0.05 [-0.57, 0.22] 0.05 [-0.56, 0.02] 0.05 [-0.57, 0.22] 0.05 [1.1.1 N-back									
$ \begin{aligned} & \operatorname{Let}(2) = 2, 2/8, 1, 3/7, 2/9, 2, 2/4, 0, 4/8, 9, 19, 3, 3/7, 8, 0, 6, 1, -0, 64, 1, 25 \\ & \operatorname{Let}(7) = 0, 24, (16^{+} - 6, 33, df = 2/9 - 0, 0.0); l^{+} = 698; \\ & \operatorname{set}(7) = 0, 24, (16^{+} - 6, 33, df = 2/9 - 0, 0.0); l^{+} = 698; \\ & \operatorname{Let}(7) = 0, 24, (16^{+} - 6, 33, df = 2/9 - 0, 0.0); l^{+} = 698; \\ & \operatorname{Let}(7) = 0, 22, 0, 13/7, 13/8, 13/8, 13/7, 13/8, 13/8, 13/8, 13/8, 10/8, 13/8, $	Kumar 2020									
bibbbai (95% C) 58 (1 - 24 C) (24 C) (25 (2 - 0.24)) (2 - 0.06) (
<pre>teterogenety: Tul* = 0.24; (bh* = 6.38, df = 2 (P = 0.04); P = 69% teterogenety: Tul* = 0.24; (bh* = 6.38, df = 2 (P = 0.04); P = 69% teterogenety: Tul* = 0.41; (bh* = 1.32, df = 3 (P = 0.03); P = 788 tetrogenety: Tul* = 0.41; (bh* = 1.32, df = 3 (P = 0.03); P = 788 tetrogenety: Tul* = 0.41; (bh* = 1.32, df = 3 (P = 0.03); P = 788 tetrogenety: Tul* = 0.41; (bh* = 1.32, df = 3 (P = 0.03); P = 788 tetrogenety: Tul* = 0.41; (bh* = 1.32, df = 3 (P = 0.03); P = 788 tetrogenety: Tul* = 0.41; (bh* = 1.32, df = 3 (P = 0.03); P = 788 tetrogenety: Tul* = 0.41; (bh* = 1.32, df = 3 (P = 0.03); P = 788 tetrogenety: Tul* = 0.41; (bh* = 1.32, df = 3 (P = 0.03); P = 788 tetrogenety: Tul* = 0.41; (bh* = 1.32, df = 3 (P = 0.03); P = 788 tetrogenety: Tul* = 0.31; (bh* 0.00); P = 0.11; P = 508 tetrogenety: Tul* = 0.31; (bh* 0.00); P = 0.11; P = 508 tetrogenety: Tul* = 0.31; (bh* 0.00); P = 0.11; P = 508 tetrogenety: Tul* = 0.31; (bh* 0.00); P = 0.11; P = 508 tetrogenety: Tul* = 0.31; (bh* 0.00); P = 0.01; P = 588 tetrogenety: Tul* = 0.31; (bh* 0.02); P = 0.01; P = 588 tetrogenety: Tul* = 0.01; (bh* 0.03); P = 0.01; P = 588 tetrogenety: Tul* = 0.02; (bh* 0.53); 103 103 103 2, 776 0.03 [-1.20, 0.57] 0.2010 0, 628 3, 374 119 6, 615 3, 34 115 2, 68 0.2010 0, 62, 0.33; 0, 41 0, 64 0, 21 P = 0.00; P = 588 tetrogenety: Tul* = 0.04; (bh* 0.43); 0 = 4, 60 0, 00; P = 588 tetrogenety: Tul* = 0.04; (bh* 0.43); 0 = 4, 64 0, 21 P = 0.00; P = 588 tetrogenety: Tul* = 0.04; (bh* 0.43); 0 = 4, 79 0, 00; P = 588 tetrogenety: Tul* = 0.04; (bh* 0.43); 0 = 4, 79 0, 00; P = 588 tetrogenety: Tul* =</pre>		2.76	1.37		2.04	0.89				
Test for overall effect: 2 – 0.32 (P = 0.75) L12 Stroop Tigs 2022 3 466 3.9 10 6.655 3.08 10 2.06 .066[-0.23, 150] Tigs 2022 1 0.65 0.11 8 57.9 146 3 15 3.55 .011[-0.80, 0.57] Tigs 2022 1.06 0.11 8 57.9 14.15 20 3.7% -0.52[-115, 0.50] Tigs 2022 1.06 0.11 8 1 7.7 14.15 20 3.7% -0.52[-115, 0.51] Tigs 2022 1.06 0.11 7 4 1.07 13 1.0 7.0 17 = 728 Test for overall effect: 2 = 0.30 P = 0.33: L13 MTA terrogeneity: Tau ² = 0.41; Ch ² = 3.72, df = 3 [P = 0.0001; P = 788] Tigs 2022 1.05 0.11 6 4.2 1 0 - 4.3 69.3 5 2.1% -0.01[-0.44, 1.06] terrogeneity: Tau ² = 0.47; Ch ² = 22.74, df = 3 (P < 0.0001; P = 878; Tigs for overall effect: 2 = 1.15 (P = 0.23): L14 MTA = 0.37; Ch ² = 22.74, df = 3 (P < 0.0001; P = 878; terrogeneity: Tau ² = 0.37; Ch ² = 22.74, df = 3 (P < 0.0001; P = 878; terrogeneity: Tau ² = 0.31; Ch ² = 0.24, df = 3 (P < 0.0001; P = 878; terrogeneity: Tau ² = 0.41; Ch ² = 1.32, df = 3 (P < 0.0001; P = 878; terrogeneity: Tau ² = 0.31; Ch ² = 0.24, df = 3 (P < 0.100; P = 878; terrogeneity: Tau ² = 0.31; Ch ² = 0.24, df = 3 (P < 0.100; P = 878; terrogeneity: Tau ² = 0.01; Ch ² = 0.23, df = 3 (P < 0.000; P = 0.03; terrogeneity: Tau ² = 0.01; Ch ² = 0.23, df = 3 (P < 0.000; P = 0.03; terrogeneity: Tau ² = 0.01; Ch ² = 0.23, df = 3 (P = 0.00; P = 0.03; terrogeneity: Tau ² = 0.01; Ch ² = 0.23, df = 3 (P = 0.00; P = 0.03; terrogeneity: Tau ² = 0.01; Ch ² = 0.23, df = 3 (P = 0.00; P = 0.03; terrogeneity: Tau ² = 0.00; Ch ² = 0.23, df = 3 (P = 0.00; P = 0.03; terrogeneity: Tau ² = 0.00; Ch ² = 0.23, df = 3 (P = 0.00; P = 0.03; terrogeneity: Tau ² = 0.00; Ch ² = 0.23, df = 3 (P = 0.00; P = 0.03; terrogeneity: Tau ² = 0.00; Ch ² = 0.23, df = 3 (P = 0.00; P = 0.03; terrogeneity: Tau ² = 0.00; Ch ² = 0.23; df = 3 (P = 0.00; P = 0.03; terrogeneity: Tau ² = 0.00; Ch ² = 0.23; df = 2 (P = 0.00; P = 1.58; terrogeneity: Tau ² = 0.00; Ch ² = 0.23; df = 2 (P = 0.00; P = 1.58; terrogeneity: Tau ² = 0.00; Ch ² = 1.59; df = 2 (P = 0.00; P = 1.58; terrogeneity: Ta		0.24. Ch	i ² - 6 -		2 (P -	0.041-1			0.11 [-0.30, 0.73]	
$ \frac{1}{1969} 2022 - 3.86 3.9 10 - 6.65 3.98 10 2.66 0.081, 159 1047 2020 44.5 5 34.5 18 87.79 14.6 15 3.55 - 0.11 - 6.80 0.57 0.0212 24.4 1.85 33 22.7 1.89 31 4.3% 0.90 [0.38, 1.41] 969 2021 2.06 0.11 01 01 72 (0.57 10 14.15 0.52 0 3.7% 0.521 [-1.06 0.07] 104 broad 105% CD 104 1.1012 = 1.37.2 (df = 3 (P = 0.003); P = 7881.1 ST MT A member 2014 - 2.1 9.2 10 - 2.1 11 5 2.1% 0.00 [-1.07, 1.07]1059 2022 5.08 17.4 (df = 3 (P = 0.003); P = 7881.1 Constrained a field of the state of the s$					- z (r =	J.J4), I	- 09%			
Limit 2020 84.56 34.65 18 87.79 14.6 15 3.5% -0.11 [-0.80, 0.57] 0.920 24.4 185 32 227. 1.89 31 4.3% -0.32 [-1.15, 0.11] 0.921 (-34, 0.48) 2.25 1.00 -0.11 20 1.13 0.15 20 3.7% -0.32 [-1.15, 0.11] 0.22 [-1.15, 0.11] 0.23 [-0.48, 0.94] terrogenety: Tau" = 0.41; Ch ⁺ = 1.372, df = 3 (P = 0.003); h ⁺ = 788 stor overall effect 2 = 0.53 (P = 0.03); L13 TMT A terrogenety: Tau" = 0.41; Ch ⁺ = 1.372, df = 3 (P = 0.003); h ⁺ = 788 stor overall effect 2 = 0.53 (P = 0.001); h ⁺ = 578; terrogenety: Tau" = 0.97; Ch ⁺ = 2.27, df = 3 (P = 0.001); h ⁺ = 578; terrogenety: Tau" = 0.97; Ch ⁺ = 2.27, df = 3 (P = 0.001); h ⁺ = 578; terrogenety: Tau" = 0.97; Ch ⁺ = 2.27, df = 3 (P = 0.001); h ⁺ = 578; terrogenety: Tau" = 0.97; Ch ⁺ = 2.27, df = 3 (P = 0.001); h ⁺ = 578; terrogenety: Tau" = 0.97; Ch ⁺ = 2.27, df = 3 (P = 0.001); h ⁺ = 578; terrogenety: Tau" = 0.12; Ch ⁺ = 0.42; h ⁺ = 0.11; h ⁺ = 500; terrogenety: Tau" = 0.13; Ch ⁺ = 0.44, df = 3 (P = 0.11); h ⁺ = 500; terrogenety: Tau" = 0.13; Ch ⁺ = 0.44, df = 3 (P = 0.11); h ⁺ = 500; terrogenety: Tau" = 0.13; Ch ⁺ = 0.44, df = 3 (P = 0.01); h ⁺ = 500; terrogenety: Tau" = 0.10; Ch ⁺ = 0.53; h ⁺ = 2.15; h ⁺ = 0.11 [-1.20, 0.57] op 2010 70; 70; 73; 72; 44; 33 10; 70; 74; 44; 31 71; 12.29; 0.01; 1.045, 0.06] inpre 2022 4.69; 0.07; 126; 53; 53; 54; -0.01; 1.05; 0.06] terrogenety: Tau" = 0.10; Ch ⁺ = 0.53; h ⁺ = 7.9; 0.55; -0.19 [-0.45; 0.05] inpre 2012 7.69; 0.13; 126; 0.90; h ⁺ = 50; terrogenety: Tau" = 0.14; Ch ⁺ = 4.73; df = 2 (P = 0.09); h ⁺ = 58; terrogenety: Tau" = 0.04; Ch ⁺ = 4.73; df = 2 (P = 0.09); h ⁺ = 58; terrogenety: Tau" = 0.04; Ch ⁺ = 4.73; df = 2 (P = 0.09); h ⁺ = 58; terrogenety: Tau" = 0.04; Ch ⁺ = 4.73; df = 2 (P = 0.09); h ⁺ = 58; terrogenety: Tau" = 0.14; Ch ⁺ = 4.73; df = 2 (P = 0.09); h ⁺ = 58; terrogenety: Tau" = 0.15; Ch ⁺ = 2.73; df = 3 0; C = 33; Z; df = 3 0; P = 0.30; h ⁺ = 0.34; h ⁺ = 0.56; h ⁺ = 2.79; df = 0.000; h ⁺ = 6.58; terrogenety: Tau" = 0.14; Ch ⁺ = 4.73; df = 2 (P = 0.09);	1.1.2 Stroop									
$ \begin{array}{c} \begin{array}{c} \begin{array}{c} \begin{array}{c} \begin{array}{c} \begin{array}{c} \begin{array}{c} \begin{array}{c}$	Figeys 2022									
leght 2022 1.06 0.11 20 1.13 0.15 20 3.7% -0.52 [-1.15, 0.1] letterogeneity: Tai ² = 0.41; (Di ² = 13.72, df = 3 (P = 0.003); I ² = 788 test for overall effect Z = 0.53 (P = 0.003); I ² = 788 test for overall effect Z = 0.54 (P = 0.003); I ² = 788 test for overall effect Z = 0.54 (P = 0.001); I ² = 538 test for overall effect Z = 1.54 (P = 0.25) L13 TM A terrogeneity: Tai ² = 0.97; (Di ² = 2.74, df = 3 (P < 0.0001); I ² = 538 test for overall effect Z = 1.15 (P = 0.21) L14 TM [S terrogeneity: Tai ² = 0.07; (Di ² = 2.274, df = 3 (P < 0.0001); I ² = 508 test for overall effect Z = 1.15 (P = 0.21) L15 Digit Span (forward) teterogeneity: Tai ² = 0.07; (Di ² = 0.21) L15 Digit Span (forward) teterogeneity: Tai ² = 0.07; (Di ² = 0.54), df = 3 (P = 0.03); I ² = 058 test for overall effect Z = 1.13 (P = 0.17) L16 Digit Span (forward) teterogeneity: Tai ² = 0.07; (Di ² = 0.54), df = 3 (P = 0.03); I ² = 058 test for overall effect Z = 1.13 (P = 0.17) L16 Digit Span (forward) teterogeneity: Tai ² = 0.07; (Di ² = 0.54), df = 3 (P = 0.03); I ² = 058 test for overall effect Z = 1.34 (P = 0.17) L16 Digit Span (forward) teterogeneity: Tai ² = 0.00; (Di ² = 0.54), df = 3 (P = 0.30); I ² = 058 test for overall effect Z = 1.34 (P = 0.07) L16 Digit Span (forward) test for overall effect Z = 1.34 (P = 0.07); I ² = 538 test for overall effect Z = 1.34 (P = 0.07); I ² = 538 test for overall effect Z = 0.14 (P = 0.89) L18 Working Memory diverogeneity: Tai ² = 0.04; (Di ² = 4.30, df = 3 (P = 0.20); I ² = 538 test for overall effect Z = 0.14 (P = 0.47); I ² = 538 test for overall effect Z = 0.14 (P = 0.48) L18 Working Memory diverogeneity: Tai ² = 0.05; (Di ² = 5.36, df = 7 (P = 0.50); I ² = 538 test for overall effect Z = 0.14 (P = 0.48) L18 Working Memory test for overall effect Z = 0.14 (P = 0.48) L18 Working Memory test for overall effect Z = 0.13 (P = 0.23); I ² = 308 test for overall effect Z = 0.13 (P = 0.39); I ² = 538 test for overall effect Z = 0.13	Kumar 2020									
ububal (95% C) 81 76 14.1% 0.23 [-0.48, 0.94] tetrograme(1): Tau" = 0.41; Ch ² = 1.32, 2d = 3 (P = 0.003); l ² = 78% Test for overall effect: 2 = 0.63 (P = 0.033) L13 TMT A terrograme(1): Tau" = 0.04; Ch ² = 0.23) L13 TMT A tetrograme(1): Tau" = 0.07; Ch ² = 2.74, df = 3 (P = 0.003); l ² = 78% Tau (1.41, 2.5, 1.42, 2.4, df = 3 (P = 0.0001); l ² = 87% Tau (1.42, 2.4, 2.4, df = 2 (P < 0.0001); l ² = 87% Tau (1.43, 2.44, 2.44, 1.44, 1.45,	_00 2012									
teterogeneity: $Tat^2 = 0.41$: $Cht^2 = 13.72$, $df = 3 (P = 0.003)$; $t^2 = 78\%$ test for overall effect: $2 = 0.63 (P = 0.53)$ L13 MTA teterogeneity: $Tat^2 = 0.21$: $D = 2.1$ 11 5 2.1% 0.00 [-1.07, 1.07] jeys 2022 2.2.2.7.4 $df = 3 (P < 0.0001)$; $t^2 = 7.\%$ L1.5 Digit Span (<i>Fourda</i>) teterogeneity: $Tat^2 = 0.32$; $Cht^2 = 22.7.4$, $df = 3 (P < 0.0001)$; $t^2 = 7.\%$ L1.5 Digit Span (<i>Fourda</i>) 10 5 3 2.7.2 4.6 $df = 3 (P < 0.0001)$; $t^2 = 7.\%$ L1.5 Digit Span (<i>Fourda</i>) 10 5 3 2.7.2 4.6 $df = 3 (P < 0.0001)$; $t^2 = 7.\%$ L1.5 Digit Span (<i>Fourda</i>) 10 5 3 2.7.2 4.6 $df = 3 (P < 0.0001)$; $t^2 = 0.0000$ tetrogeneity: $Tat^2 = 0.31$; $Cht^2 = 6.2.4$ L1.6 (D0.6.0.6.088] 10 5 3 2.1.3 19 5 6.69 1.8.51 15 3.4.4% 0.26 [-0.2.7, 1.20] 0.33 [-0.18, 0.84] 11.5 Digit Span (<i>Fourda</i>) 11.5 Digit Span (<i>Fourda</i>) 11.5 Digit Span (<i>Fourda</i>) 11.6 Digit Span (<i>Fourda</i>) 12.66 9.0.97 10 5.33 1.07 10 2.7% -0.33 [-1.27, 0.50] 11.7 Sin MT 11.6 Digit Span (<i>Fourda</i>) 11.8 Digit Span (<i>Fourda</i>) 11.9 0.0.65 19 7.13 0.9 4 1.5.0% 0.0.7 (<i>F</i> 0.50, 0.23] 11.15 Digit Span (<i>Fourda</i>) 11.16 Digit Span (<i>Fourda</i>) 11.17 SDMT 11.16 Digit Span (<i>Fourda</i>) 11.17 SDMT 11.16 Digit Span (<i>Fourda</i>) 11.16 Digit Span (<i>Fourda</i>) 11.16 Digit Span (<i>Fourda</i>) 11.17 SDMT 11.16 Digit Span (<i>Fourda</i>) 11.17 SDMT 11.17 SDMT 11.18 Digit Span (<i>Fourda</i>) 11.18 Digit 		1.06	0.11		1.13	0.15				
Test for overall effect: Z = 0.63 (P = 0.53) LL3 TMT_A fermabl 2014 -2.1 9.2 10 -2.1 11 5 2.1% 0.00 [-1.07, 1.07] igeys 2022 5.0.8 1 17.44 10 40.13 14.48 10 2.0% 0.64 [-0.27, 1.54] igeys 2022 5.0.8 1 17.44 10 40.13 14.48 10 2.0% 0.64 [-0.27, 1.54] interogenety: Tar - 0.97, Ch ² = 2.74, df = 3 (P < 0.0001); P = 87% Test for overall effect: Z = 1.15 (P = 0.25) LL4 TMT_B ferrogenety: Tar - 0.37, Ch ² = 2.74, df = 3 (P < 0.0001); P = 87% Test for overall effect: Z = 1.15 (P = 0.25) LL4 TMT_B ferrogenety: Tar - 0.37, Ch ² = 2.04 (D = 0.43) 5 2.1% -0.11 [-1.19, 0.96] igeys 2022 130.61 45.74 10 86.27 24.07 10 2.4% 1.16 (0.20, 2.13) oz 2010 7.57 5 2.14 19 55.09 16.51 15 3.4% 0.52 [-0.17, 1.20] odd renzo 2019 (C = 2.15) LL4 TMT_B ferrogenety: Tar - 0.15; Ch ² = 0.58, df = 3 (P = 0.11); P = 50% set for overall effect: Z = 1.25 (P = 0.21) LL5 Digit Span (forward) igeys 2022 3.46 0.97 10 5.39 1.07 10 2.7% -0.38 [-1.27, 0.50] oz 2010 8.68 2.31 19 8.68 2.05 15 3.5% 0.00 [-0.68, 0.68] oz 2010 8.68 2.31 19 8.68 2.05 15 3.5% 0.00 [-0.68, 0.68] jeer ogenety: Tar - 0.00; Ch ² = 0.58, df = 3 (P = 0.09); P = 0.58 set for overall effect Z = 1.32 (P = 0.09); P = 0.58 is 15 3.4% 0.05 [-1.20, 0.57] oz 2010 7.66 0.55 19 7.39 0.55 15 3.4% 0.05 [-1.20, 0.57] oz 2010 7.66 0.55 19 7.39 0.55 15 3.4% 0.05 [-1.20, 0.57] oz 2010 7.66 0.55 19 7.39 0.55 15 3.4% 0.02 [-0.37, 0.42] idetrogenetity: Tar - 0.04; Ch ² = 0.58, df = 3 (P = 0.09); P = 30% test for overall effect Z = -0.14 (P = 0.87) LL3 Digit Span (factward) iggys 2022 2.976 10.65 10 3.479 10.54 10 2.27% -0.31 [-1.20, 0.57] oz 2010 7.66 0.55 19 7.39 0.55 15 3.4% 0.05 [-0.37, 0.42] idetrogenetity: Tar - 0.41; Ch ² = 0.73 LL3 Sim is for overall effect Z = -0.14 (P = 0.02); P = 31% test for overall effect Z = -0.14 (P = 0.02); P = 31% test for overall effect Z = 0.34 (P = 0.00001); P = 63% test for overall effect Z = 0.34 (P = 0.00001); P = 35% test for overall effect Z = 0.13 (P = 0.0001); P = 35% test for overall effect Z = -1.30 (P = 0.13) te		0 41. 64	12 - 17		- 2 /D	- 0.007			0.25 [-0.46, 0.94]	
lemnals 2014 -2.1 9.2 10 -2.1 11 15 2.1% 0.00 [-1.07, 1.07] gives 2022 50.8 17.44 10 40.13 14.48 10 2.6% 0.64 [-0.27, 1.54] on 2010 44.89 2.95 19 38.67 2.95 15 2.8% 2.06 [1.20, 291] on 2010 38.65 14.07 64 41.62 1062 41 5.0% -0.16 [-0.44, 1.66] letterogenety: Tar ² - 0.97; Ch ² = 2.74, df = 3 ($P < 0.0001$); l ² = 87% fest for overall effect $Z = 1.15$ ($P = 0.25$) 1.14 TMT B letterogenety: Tar ² - 0.97; Ch ² = 2.74, df = 3 ($P < 0.0001$); l ² = 87% fest for overall effect $Z = 1.15$ ($P = 0.25$) 1.14 TMT B letterogenety: Tar ² - 0.07; Ch ² = 0.43 ($P = 0.21$) 1.15 Opit Span (Forward) igeys 2022 130.61 45.74 10 86.27 24.07 10 2.4% 1.16 (0.20, 2.13] on 2010 75.75 2.14 19 6.6.9 df 3 ($P = 0.11$); l ² = 50% est for overall effect $Z = 1.25$ ($P = 0.21$) 1.15 Opit Span (Forward) igeys 2022 4.98 0.97 10 5.39 1.07 10 2.7% -0.38 [-1.27, 0.50] on 2010 8.68 2.31 19 8.68 2.05 15 3.5% 0.00 [-0.68, 0.68] on 2010 8.68 2.31 19 8.68 2.05 15 3.5% -0.017 [-0.56, 0.23] Unitotal (95% CD) 12.6 97 15.5% -0.19 [-0.45, 0.08] ieterogenety: Tar ² = 0.00; Ch ² = 0.58, df = 3 ($P = 0.30$); l ² = 0% letterogenety: Tar ² = 0.00; Ch ² = 0.58, df = 3 ($P = 0.30$); l ² = 0% letterogenety: Tar ² = 0.04; Ch ² = 4.78, 0.13 ($P = 0.30$); l ² = 0% letterogenety: Tar ² = 0.04; Ch ² = 4.79, 0.59 10 7.38 ($P = 0.30$; l ² = 0% letterogenety: Tar ² = 0.43, 0.df = 3 ($P = 0.30$; l ² = 0% letterogenety: Tar ² = 0.43, 0.df = 3 ($P = 0.30$; l ² = 0% letterogenety: Tar ² = 0.44; Ch ² = 4.74, df = 2 ($P = 0.30$; l ² = 0% letterogenety: Tar ² = 0.44; Ch ² = 4.74, df = 2 ($P = 0.00000$; l ² = 5% letterogenety: Tar ² = 0.14; (Ch ² = 4.74, df = 2 ($P = 0.000001$; l ² = 5% letterogenety: Tar ² = 0.14; (Ch ² = 4.74, df = 2 ($P = 0.00001$; l ² = 5% letterogenety: Tar ² = 0.14; (Ch ² = 4.74, df = 2 ($P = 0.00001$; l ² = 5% letterogenety: Tar ² = 0.14; (Ch ² = 4.74, df = 2 ($P = 0.00001$; l ² = 6% letterogenety: Tar ² = 0.14; (Ch ² = 4.74, df = 2 ($P = 0.00001$; l ² = 6% letter					- 3 (P =	- 0.003	, 1 = 7	070		
igey 2022 50.81 17.44 10 40.13 14.48 10 2.6% 0.64 [-0.27, 154] 2.00 2010 44.89 2.95 19 3.8.67 2.95 15 2.8% 2.06 [-0.27, 154] 2.07 64 41.62 19.62 41 5.0% -0.18 [-0.57, 0.21] 0.17 120 103 771 12.4% 0.61 [-0.44, 1.66] 0.57, 0.21] 0.17 120 103 771 12.4% 0.61 [-0.44, 1.66] 0.27, 121 10 104 19.57 (-0.21) 104 19.57 (-0.21) 104 19.51 15 15 104 1104 19.57 (-0.21) 105 115 15 104 1104 19.57 (-0.21) 105 115 15 104 1104 19.57 (-0.21) 105 115 15 104 1104 19.57 (-0.21) 105 115 15 104 1104 19.57 (-0.21) 105 115 15 104 1104 19.57 (-0.21) 105 115 15 15 104 110 104 19.57 (-0.21) 105 115 15 15 104 110 104 19.57 (-0.21) 103 17 11 2.29% 0.33 [-0.18, 0.84] 104 109 104 19.57 (-0.21) 103 17 11 2.29% 0.33 [-0.18, 0.84] 104 109 104 19.57 (-0.21) 103 17 11 2.29% 0.33 [-0.18, 0.84] 106 105 2.7% -0.38 [-1.27, 0.50] 106 2010 2.68, 0.68 10.8 10 2.7% -0.38 [-1.27, 0.50] 106 2010 2.68, 0.58 10 2.7% -0.31 [-1.20, 0.57] 105 2010 2.58, 0f -31 (P = 0.09); P = 0.58 10.00% -0.17 [-0.45, 0.08] 104 109 19.57 10 3.57 10 3.57 10.50% 0.02 [-0.45, 0.23] 104 126 7 99 7 15.5% -0.01 [-0.45, 0.08] 104 109 19.57 10 3.57 10.59	1.1.3 TMT_A									
$ \begin{array}{c} \begin{array}{c} \begin{array}{c} \begin{array}{c} \begin{array}{c} \begin{array}{c} \begin{array}{c} \begin{array}{c}$	3ennabi 2014									
doreno 2019 38.65 14.07 64 41.62 19.62 41 5.0% -0.18 [-0.7, 0.21] teterogenetity: Tau ² = 0.97; Chi ² = 22.74, df = 3 ($P < 0.0001$); $I2 = 87%$ test for overall effect: $Z = 1.15$ ($P = 0.25$) LL4 TMT_B teterogenetity: Tau ² = 0.97; Chi ² = 22.74, df = 3 ($P < 0.0001$); $I2 = 87%$ teterogenetity: Tau ² = 0.13; Chi ² = 6.04, df = 3 ($P < 0.1001$); $I2 = 50\%$ teterogenetity: Tau ² = 0.13; Chi ² = 6.04, df = 3 ($P = 0.11$); $I2 = 50\%$ teterogenetity: Tau ² = 0.13; Chi ² = 6.04, df = 3 ($P = 0.11$); $I2 = 50\%$ teterogenetity: Tau ² = 0.13; Chi ² = 6.04, df = 3 ($P = 0.11$); $I2 = 50\%$ teterogenetity: Tau ² = 0.12; Chi ² = 0.58, df = 3 ($P = 0.000$); $I2 = 0.0\%$ teterogenetity: Tau ² = 0.00; Chi ² = 0.58, df = 3 ($P = 0.000$); $I2 = 0.0\%$ teterogenetity: Tau ² = 0.00; Chi ² = 0.58, df = 3 ($P = 0.000$); $I2 = 0.0\%$ teterogenetity: Tau ² = 0.00; Chi ² = 0.58, df = 3 ($P = 0.20$); $I2 = 0.0\%$ teterogenetity: Tau ² = 0.00; Chi ² = 0.58, df = 3 ($P = 0.20$); $I2 = 0.0\%$ teterogenetity: Tau ² = 0.00; Chi ² = 0.58, df = 3 ($P = 0.20$); $I2 = 0.0\%$ teterogenetity: Tau ² = 0.04; Chi ² = 0.58, df = 3 ($P = 0.20$); $I2 = 0.0\%$ teterogenetity: Tau ² = 0.04; Chi ² = 4.30, df = 3 ($P = 0.23$); $I2 = 30\%$ teterogenetity: Tau ² = 0.04; Chi ² = 4.74, df = 2 ($P = 0.09$); $I2 = 30\%$ teterogenetity: Tau ² = 0.04; Chi ² = 4.73, df = 2 ($P = 0.09$); $I2 = 30\%$ teterogenetity: Tau ² = 0.04; Chi ² = 4.74, df = 2 ($P = 0.09$); $I2 = 58\%$ teterogenetity: Tau ² = 0.04; Chi ² = 4.73, df = 2 ($P = 0.09$); $I2 = 58\%$ tetrogenetity: Tau ² = 0.04; Chi ² = 4.73, df = 2 ($P = 0.09$); $I2 = 58\%$ tetrogenetity: Tau ² = 0.04; Chi ² = 4.73, df = 2 ($P = 0.09$); $I2 = 58\%$ tetrogenetity: Tau ² = 0.04; Chi ² = 4.74, df = 2 ($P = 0.09$); $I2 = 58\%$ tetrogenetity: Tau ² = 0.04; Chi ² = 5.75, 161; 12; 2, 2.8\%, 1.02 [0.16, 1.38] tetrogenetity: Tau ² = 0.04; Chi ² = 5.75, 161; 12; 2, 2.8\%, 1.02 [0.16, 1.05] teterogenetity: Tau ² = 0.04; Chi ²	Figeys 2022									
bubboal (95% C) 103 71 12.4% 0.61 [-0.44, 1.66] thereorgeneity: Tau ² = 0.27; Ch ² = 2.274, df = 3 (P < 0.0001); l ² = 87% Test for overall effect: $Z = 1.15 (P = 0.25)$ L1.4 TM T, B termabl 2014 -51.1 6.8.2 10 -43 69.3 5 2.1% -0.11 [-1.19, 0.96] tigeys 2022 130.61 45.74 10 86.27 24.07 10 2.4% 1.16 [0.20, 2.13] oo 2010 75.75 21.4 19 65.09 185.1 15 3.4% 0.52 [-0.17, 1.20] dorena 2019 76.35 37.23 64 76.72 44.81 41 5.0% -0.01 [-0.40, 0.38] teterogeneity: Tau ² = 0.13; Ch ² = 6.04, df = 3 (P = 0.11); l ² = 50% Test for overall effect: $Z = 1.25 (P = 0.21)$ L1.5 Digit Span (Forward) tigeys 2022 4.98 0.97 10 5.39 1.07 10 2.7% -0.38 [-1.27, 0.50] oo 2010 8.68 2.31 19 8.68 2.05 15 3.5% 0.00 [-0.68, 0.68] ubtotal (95% C) 97 15.5% -0.19 [-0.45, 0.08] teterogeneity: Tau ² = 0.03; Ch ² = 0.58, df = 3 (P = 0.90); l ² = 0% Test for overall effect: $Z = 1.38 (P = 0.17)$ L1.5 Digit Span (Eackward) tigeys 2022 3.46 0.99 10 3.8 1.08 10 2.7% -0.31 [-1.20, 0.57] oo 2010 7.06 0.55 13 7.72 0.58 at 15 3.4% 0.57 [-0.23, 0.75] teterogeneity: Tau ² = 0.03; Ch ² = 0.58, df = 3 (P = 0.23); l ² = 30% Test for overall effect: $Z = 0.34 (P = 0.73)$ L1.7 SDMT tigeys 2022 2.9.76 10.65 10 34.79 10.54 10 2.6% -0.45 [-1.35, 0.44] to 2012 7.35 0.55 13 7.7 15.5% -0.06 [-0.46, 0.028] teterogeneity: Tau ² = 0.14; Ch ² = 4.74, df = 2 (P = 0.09); l ² = 58% Test for overall effect: $Z = 0.14 (P = 0.89)$ L1.17 SDMT teterogeneity: Tau ² = 0.14; Ch ² = 4.74, df = 2 (P = 0.09); l ² = 58% Test for overall effect: $Z = 0.14 (P = 0.49)$ teterogeneity: Tau ² = 0.49; Ch ² = 5.19, df = 1 (P = 0.02); l ² = 58% Test for overall effect: $Z = 0.14 (P = 0.49)$ Total (95% C) 766 585 100.00%; 0.13 [-0.06, 0.21] teterogeneity: Tau ² = 0.49; Ch ² = 5.19, df = 1 (P = 0.02); l ² = 58% Test for overall effect: $Z = 0.14 (P = 0.49)$ Total (95% C) 766 585 100.00%; 0.13 [-0.06, 0.32] Test for overall effect: $Z = 0.14 (P = 0.49)$ Total (95% C) 766 585 100.00%; 0.13 [-0.06, 0.32] Testor overall effect: $Z = 0.14 (P = $	_00 2010									
teterogeneity: $Tau^2 = 0.97$; $Ch^2 = 22.74$, $df = 3$ ($P < 0.0001$); $l^2 = 87\%$ first or overall effect: $Z = 1.15$ ($P = 0.25$) LL4 TMT_8 teterogeneity: $Tau^2 = 0.13$; $Ch^2 = 0.25$ LL4 TM 5 teterogeneity: $Tau^2 = 0.13$; $Ch^2 = 0.25$ LL5 Digit Span (Forward) tigeys 2022 4.98 0.97 10 5.39 1.07 10 2.7% -0.38 $[-1.27, 0.50]$ 0.33 $[-0.18, 0.84]teterogeneity: Tau^2 = 0.01; Ch^2 = 0.43; e = 0.11); l^2 = 50\%teterogeneity: Tau^2 = 0.01; Ch^2 = 0.43; a = 0, (P = 0.11); l^2 = 0.01LL5 Digit Span (Forward)tigeys 2022 4.98 0.97 10 5.39 1.07 10 2.7\% -0.38 [-1.27, 0.50]o a 2010$ 8.68 2.31 19 8.68 2.05 15 $3.3%$ 0.00 $[-0.45, 0.23]0.02010$ 8.68 2.31 19 8.68 2.05 15 $3.5%$ 0.00 $[-0.45, 0.23]0.02010 0.05 Ch^2 = 0.58, df = 3 (P = 0.90); l^2 = 0\%teterogeneity: Tau^2 = 0.00; Ch^2 = 0.53, df = 3 (P = 0.29); l^2 = 0\%teterogeneity: Tau^2 = 0.04; Ch^2 = 4.30, df = 3 (P = 0.29); l^2 = 0\%teterogeneity: Tau^2 = 0.04; Ch^2 = 4.30, df = 3 (P = 0.23); l^2 = 0\%teterogeneity: Tau^2 = 0.04; Ch^2 = 4.30, df = 3 (P = 0.23); l^2 = 30\%teterogeneity: Tau^2 = 0.04; Ch^2 = 4.30, df = 3 (P = 0.23); l^2 = 30\%teterogeneity: Tau^2 = 0.04; Ch^2 = 4.30, df = 3 (P = 0.23); l^2 = 30\%teterogeneity: Tau^2 = 0.04; Ch^2 = 4.74, df = 2 (P = 0.09); l^2 = 58\%teterogeneity: Tau^2 = 0.04; Ch^2 = 4.73, df = 2 (P = 0.09); l^2 = 58\%teterogeneity: Tau^2 = 0.04; Ch^2 = 5.35, df = 27 (P = 0.090); l^2 = 58\%tetrogeneity: Tau^2 = 0.14; Ch^2 = 7.23, df = 2.27 (P = 0.00000); l^2 = 6.3\%1.18 Working Memorydoterog 2010 71 15.86 2.32 12 12 13.75 1.61 12 2.2\% 1.02 (0.16, 1.038]1.18 Working Memorydoterogeneity: Tau^2 = 0.14; Ch^2 = 7.236, df = 2.7 (P = 0.020); l^2 = 6.3\%tetrogeneity: Tau^2 = 0.14; Ch^2 = 7.236, df = 2.7 (P = 0.020); l^2 = 6.3\%1.18 Working Memorydoterogeneity: Tau^2 = 0.14; Ch^2$		38.65	14.07		41.62	19.62				
Test for overall effect: $Z = 1.15$ ($P = 0.25$) L14 TMT B lemnabl 2014 rotation 1014 rotation 1015 rotation 101		0.07. 61	12 22		2 /0	. 0.000			0.01 [-0.44, 1.66]	
lemenab 2014 -51.1 68.2 10 -43 69.3 5 2.1% $-0.11[-1]9, 0.96]$ jacy 2022 130.61 457.4 10 86.72 24.07 10 2.4% $1.16[0.20, 213]$ and 2010 75.75 21.4 19 65.09 18.51 15 3.4% $0.52[-0.17, 1.20]$ hobtoal (95% CI) 60.4, 6f = 3 (P = 0.11); I ² = 50% Test for overall effect: Z = 1.25 (P = 0.21) L15 Diglt Span (forward) jacys 2022 4.98 0.97 10 5.39 1.07 10 2.7% $-0.38[-1.27, 0.50]$ and 2010 8.68 2.31 19 8.68 2.05 15 3.5% $-0.02[-0.57, 0.23]$ hottoal (95% CI) 126 (4.433 41) 1.2 6.67 3.1 4.4% $-0.26[-0.75, 0.23]$ hottoal (95% CI) 126 (4.433 6.11) 2.67 3.1 4.4% $-0.26[-0.75, 0.26]$ heterogeneity: Tau ² = 0.00; Chi ² = 0.58, ff = 3 (P = 0.90); I ² = 0% Test for overall effect: Z = 1.38 (P = 0.90); I ² = 0% Test for overall effect: Z = 0.34 (P = 0.73) L15 Diglt Span (forward) jacys 2022 3.46 0.99 10 3.8 1.08 10 2.7% $-0.31[-1.20, 0.57]$ and 2010 7.66 0.55 19 7.73 0.555 13.4% $-0.26[-0.75, 0.26]$ heterogeneity: Tau ² = 0.00; Chi ² = 0.58, ff = 3 (P = 0.23); I ² = 0% Test for overall effect: Z = 0.34 (P = 0.73) L1.7 SDMT jacys 2022 2.9.76 10.655 10 3.479 10.54 10 2.6% $-0.45[-1.35, 0.44]$ jacys 2019 6.22 3.374 19 60.16 3.43 15 3.4% $-0.26[-0.76, 0.28]$ heterogeneity: Tau ² = 0.47 (Chi ² = 4.74, df = 2 (P = 0.09); I ² = 58% test for overall effect: Z = 0.34 (P = 0.73) L1.7 SDMT jacys 2022 2.9.76 10.65 10 3.479 10.54 10 2.6% $-0.46[-0.47, 0.31]$ heterogeneity: Tau ² = 0.47 (Chi ² = 5.19, df = 1 (P = 0.02); I ² = 58% test for overall effect: Z = 0.74 (P = 0.59) L1.8 Working Memory heterogeneity: Tau ² = 0.47 (Chi ² = 5.19, df = 1 (P = 0.02); I ² = 63% test for overall effect: Z = 0.74 (P = 0.59) L18 Working Memory heterogeneity: Tau ² = 0.47 (Chi ² = 5.19, df = 1 (P = 0.02); I ² = 63% test for overall effect: Z = 0.74 (P = 0.59) L18 Working Memory heterogeneity: Tau ² = 0.47 (Chi ² = 5.19, df = 1 (P = 0.02); I ² = 63% test for overall effect: Z = 0.34 (F = 0.79) Total (95% C) 76 2.56 5.51 9.70 (F = 7.2.35, df = 2.7 (P < 0.00001); I ² = 63% test for overall effect: Z					= 3 (P <	< 0.000	1); l ² =	87%		
igeys 2022 130.61 4574 10 86.27 24.07 10 2.4% 1.16 [0.20, 2.13] oo 2010 76.75 37.23 64 76.72 44.81 41 5.34% 0.52 [-0.17, 1.20] of 2019 76.35 37.23 64 76.72 44.81 41 5.0% -0.01 [-0.40, 0.38] otheroa 2019 76.35 37.23 64 76.72 44.81 41 5.0% -0.01 [-0.40, 0.38] otheroa 2019 76.35 37.23 64 76.72 44.81 41 5.0% -0.01 [-0.40, 0.38] otheroa 2019 76.35 37.23 64 76.72 44.81 41 5.0% -0.01 [-0.40, 0.38] otheroa 2019 76.35 37.23 64 76.72 44.81 41 5.0% -0.38 [-1.27, 0.50] igeys 2022 4.98 0.97 10 5.39 1.07 10 7.7% -0.38 [-1.27, 0.50] oo 2010 8.68 2.31 11 8.68 2.05 15 3.3.% 0.00 [-0.68, 0.68] oo 2012 10.4 2.64 33 1.11 2.67 31 4.4% -0.26 [-0.75, 0.23] otheroa 2019 8.38 2.14 64 8.73 1.99 41 5.0% -0.17 [-0.56, 0.23] intercogenetity: Tau ² = 0.00; Chi ² = 0.58, df = 3 (P = 0.90); i ² = 0% fest for overall effect: 2 = 1.38 (P = 0.17) L1.6 Digit Span (Backward) igeys 2022 3.46 0.99 10 3.8 108 10 2.7% -0.31 [-1.20, 0.57] oo 2010 7.06 0.55 119 7.39 0.55 15 3.4% -0.59 [-1.28, 0.11] oo 2012 7.35 0.55 13 3.7.2 0.58 31 4.4% 0.26 [-0.23, 0.75] otheroa 2019 5.74 2.17 64 5.69 1.83 31 5.5% -0.06 [-0.40, 0.28] teterogenety: Tau ² = 0.04; (Chi ² = 4.30, df = 3 (P = 0.23); i ² = 30% fest for overall effect: Z = -1.84 (P = 0.73) L1.17 SDMT igeys 2022 2.9.76 10.65 10 34.79 10.54 10 2.6% -0.45 [-1.35, 0.44] oo 2010 62.28 3.74 19 60.16 3.43 15 3.4% 0.57 [-0.12, 1.27] otheroa 2019 0.51 0.18 64 0.56 0.24 41 5.0% -0.04 [-0.61, 0.53] teterogenety: Tau ² = 0.49; (Chi ² = 4.74, df = 2 (P = 0.09); i ² = 58% fest for overall effect: Z = -0.34 (P = 0.48) L1.8 Working Memory Acrem 2019 0.14 0.94 64 0.21 0.8 41 5.0% -0.08 [-0.47, 0.31] alehingid 2017 13.86 2.32 12 13.75 1.61 12 2.8% 1.02 [0.16, 1.88] isothor averall effect: Z = -1.30 (P = 0.19) rest for sourcal leftect: Z = -1.30 (F = 0.19) rest rest or overall effect: Z = -1.30 (F = 0.79) rest rest or overall effect: Z = -1.30 (F = 0.79) rest rest or overall effect: Z = -1.30 (F = 0.19) rest rest or overall effect: Z = -1.30 (F = 0.19) rest rest or overall effect: Z = -1	1.1.4 TMT_B									
$ \begin{array}{c} \begin{array}{c} \begin{array}{c} \begin{array}{c} \begin{array}{c} \begin{array}{c} \begin{array}{c} \begin{array}{c}$	Bennabi 2014									
doceno 2019 76.35 37.23 64 76.72 44.81 41 5.0% -0.01 [-0.40, 0.38] distoral (95% C) 103 71 12.9% 0.33 [-0.18, 0.84] decrogeneity: Tau" = 0.13; Ch ² = 6.04, df = 3 (P = 0.11); l ² = 50% fest for overall effect: Z = 1.25 (P = 0.21) L1.5 Digit Span (Forward) giegy 2022 4.98 0.97 10 5.39 1.07 10 2.7% -0.38 [-1.27, 0.50] oo 2010 8.68 2.31 19 8.68 2.05 15 3.3% 0.00 [-0.668, 0.68] oo 2011 10.4 2.64 33 11.1 2.67 31 4.4% -0.26 [-0.75, 0.23] doreno 2019 8.38 2.14 64 8.73 1.99 41 5.0% -0.17 [-0.56, 0.23] distoral offsc C) 126 9.09(); l ² = 0.58, df = 3 (P = 0.90); l ² = 0% fest for overall effect: Z = 1.38 (P = 0.17) L1.6 Digit Span (Backward) igey 2022 3.46 0.99 10 3.8 1.08 10 2.7% -0.31 [-1.20, 0.57] igey 2022 3.46 0.99 10 3.8 1.08 10 2.7% -0.39 [-1.28, 0.11] oo 2010 7.06 0.55 19 7.39 0.55 15 3.4% 0.02 [-0.23, 0.75] oo 2010 7.06 0.55 19 7.39 0.55 15 3.4% 0.02 [-0.23, 0.75] ideterogeneity: Tau" = 0.04; Ch ² = 4.30, df = 3 (P = 0.23); l ² = 30% fest for overall effect: Z = 0.34 (P = 0.73) L1.7 SDMT igey 2022 29.76 10.65 10 34.79 10.54 10 2.6% -0.45 [-1.35, 0.44] oo 2010 62.28 3.74 19 60.163 3.43 15 3.4% 0.57 [-0.12, 1.27] doreno 2019 0.51 0.18 64 0.56 0.24 41 5.0% -0.24 [-0.64, 0.15] idetrogeneity: Tau" = 0.14; Ch ² = 4.74, df = 2 (P = 0.09); l ² = 58% fest for overall effect: Z = 0.14 (P = 0.89) L1.8 Working Memory doreno 2019 0.14 0.94 64 0.21 0.8 41 5.0% -0.08 [-0.47, 0.31] iaehinejd 2017 766 585 100.0% 0.13 [-0.06, 0.32] teterogeneity: Tau" = 0.49; Ch ² = 5.19, df = 1 (P = 0.02); l ² = 63% fest for overall effect: Z = 0.74 (P = 0.46) Total (95% CI) 766 585 100.0% fotal (95% CI) 766 585 100.0% fotal (95% CI) 766 585 100.0% fest for overall effect: Z = 0.73, df = 27 (P < 0.00001); l ² = 63% fest for overall effect: Z = 0.74 (P = 0.46] Test for overall effect: Z = 1.97, df = 1 (P = 0.02); l ² = 63% fest for overall effect: Z = 0.74 (P = 0.46] Test for overall effect: Z = 5.96, df = 7 (P = 0.54), l ² = 0% Test for overall effect: Z = 5.96, df = 7 (P = 0.54), l ² = 0%	Figeys 2022									
Jubical (95% C) 103 71 12.9% 0.33 [-0.18, 0.84] Testerogeneity: Tau ² = 0.13; Ch ² = 5.04, df = 3 (P = 0.11); l ² = 50% Test for overall effect: Z = 1.25 (P = 0.21) LLS Digit Span (Forward) Tigeys 2022 4.98 0.97 10 5.39 1.07 10 2.7% -0.38 [-1.27, 0.50] too 2010 8.68 2.31 19 8.68 2.05 15 3.5% 0.00 [-0.68, 0.68] too 2012 10.4 2.64 33 11.1 2.67 31 4.4% -0.26 [-0.75, 0.23] too 2012 10.4 2.64 33 11.2 2.67 94 15.0% Test for overall effect: Z = 1.38 (P = 0.90); l ² = 0% Test for overall effect: Z = 1.38 (P = 0.90); l ² = 0% Test for overall effect: Z = 1.38 (P = 0.90); l ² = 0% Test for overall effect: Z = 0.34 (P = 0.73) LLS Digit Span (Backward) Tigeys 2022 3.46 0.99 10 3.8 1.08 10 2.7% -0.31 [-1.20, 0.57] too 2010 7.06 0.55 19 7.39 0.55 15 3.4% -0.59 [-1.28, 0.11] LLS Digit Span (Backward) Tigeys 2022 3.46 0.99 10 3.8 1.08 10 2.7% -0.31 [-1.20, 0.57] too 2010 7.06 0.55 19 7.39 0.55 15 3.4% -0.26 [-0.37, 0.42] Ubbtotal (95% C) 126 97 15.5% -0.06 [-0.40, 0.28] teterogeneity: Tau ² = 0.04; Ch ² = 4.30, df = 3 (P = 0.23); l ² = 30% Test for overall effect: Z = 0.34 (P = 0.73) LLS Voltati (95% C) 126 97 15.5% -0.06 [-0.40, 0.28] Test for overall effect: Z = 0.14 (P = 0.73) LLS Digit Span (Figure 2019 0.14 0.94 64 0.51 0.24 1.50% -0.04 [-0.64, 0.15] Tigeys 2022 2.9.76 10.65 10 34.79 10.54 10 2.6% -0.04 [-0.61, 0.53] Test for overall effect: Z = 0.14 (P = 0.89) LLS Working Memory Test for overall effect: Z = 0.14 (P = 0.89) LLS Working Memory Test for overall effect: Z = 0.74 (P = 0.49) Test for overall effect: Z = 0.74 (P = 0.49) Test for overall effect: Z = 0.74 (P = 0.49) Test for overall effect: Z = 0.74 (P = 0.49) Test for overall effect: Z = 0.74 (P = 0.49) Test for overall effect: Z = 1.30 (P = 0.54), l ² = 63% Test for overall effect: Z = 1.30 (f = 27 (P = 0.0001); l ² = 63% Test for overall effect: Z = 0.74 (P = 0.54), l ² = 0.94 Test for overall effect: Z = 1.30 (f = 27 (P = 0.0001); l ² = 63% Test for overall effect: Z = 1.30 (f = 0.79) Test for overall effec										
teterogeneity: Tau ² = 0.13; Ch ² = 6.04, df = 3 (P = 0.11); l ² = 50% test for overall effect: Z = 1.25 (P = 0.21) L1.5 Digit Span (Forward) igeys 2022 4.98 0.97 10 5.39 1.07 10 2.7% -0.38 [-1.27, 0.50] oo 2010 8.68 2.31 19 8.68 2.05 15 3.5% 0.00 [-0.68, 0.68] oo 2011 10.4 2.64 33 1.11 2.67 31 4.4% -0.26 [-0.75, 0.23] doreno 2019 8.38 2.14 64 8.73 1.99 41 5.0% -0.17 [-0.56, 0.23] doreno 2019 8.38 2.14 64 8.73 1.99 41 5.0% -0.17 [-0.56, 0.23] doreno 2019 8.38 2.14 64 8.73 1.99 41 5.0% -0.17 [-0.56, 0.23] doreno 2019 0.706 0.55 19 7.39 0.55 15 3.4% -0.59 [-1.28, 0.11] oo 2010 7.06 0.55 19 7.39 0.55 13 4.4% 0.26 [-0.23, 0.75] doreno 2019 5.74 2.17 64 5.69 1.83 41 5.0% 0.02 [-0.37, 0.42] doreno 2019 5.74 2.17 64 5.69 1.83 41 5.0% 0.02 [-0.37, 0.42] doreno 2019 0.51 0.18 64 0.56 0.24 41 5.0% -0.04 [-0.60, 0.28] teterogeneity: Tau ² = 0.04; Ch ² = 4.74, df = 2 (P = 0.29); l ² = 30% test for overall effect: Z = 0.14 (P = 0.73) L1.7 SDMT igeys 2022 29.76 10.65 10 34.79 10.54 10 2.6% -0.45 [-1.35, 0.44] doreno 2019 0.51 0.18 64 0.56 0.24 41 5.0% -0.08 [-0.47, 0.31] doreno 2019 0.51 0.18 64 0.56 0.24 41 5.0% -0.08 [-0.47, 0.31] doreno 2019 0.51 0.18 64 0.55 0.24 41 5.0% -0.08 [-0.47, 0.31] deterogeneity: Tau ² = 0.49; Ch ² = 4.74, df = 2 (P = 0.09); l ² = 58% test for overall effect: Z = 0.14 (P = 0.89) L1.8 Working Memory doreno 2019 0.14 0.94 64 0.21 0.8 41 5.0% -0.08 [-0.47, 0.31] daehingad 2017 15.86 2.32 12 13.75 1.61 12 2.8% 1.02 [0.16, 1.83] teterogeneity: Tau ² = 0.49; Ch ² = 4.79, df = 1 (P = 0.02); l ² = 81% test for overall effect: Z = 0.74 (P = 0.46) Test for overall effect: Z = 0.74 (P = 0.46) Test for overall effect: Z = 0.74 (P = 0.46) Test for overall effect: Z = 0.74 (D = 0.16) Test for overall effect: Z = 0.74 (D = 0.16) Test for overall effect: Z = 5.96, df = 7 (P = 0.54), l ² = 0% Test for overall effect: Z = 5.96, df = 7 (P = 0.54), l ² = 0% Test for overall effect: Z = 5.96, df = 7 (P = 0.54), l ² = 0%		76.35	37.23		76.72	44.81				
L1.5 Digit Span (Forward) igeys 2022 4.98 0.97 10 5.39 1.07 10 2.7% -0.38 [-1.27, 0.50] oo 2010 8.68 2.31 19 8.68 2.05 15 3.5% -0.00 [-0.68, 0.68] oo 2011 10.4 2.64 33 11.1 2.67 31 4.4% -0.26 [-0.75, 0.23] doreno 2019 8.38 2.14 64 8.73 1.99 41 5.0% -0.017 [-0.56, 0.28] doreno 2019 8.38 2.14 64 8.73 1.99 41 5.0% -0.017 [-0.56, 0.28] teterogeneity: Tau ² = 0.00; Ch ² = 0.58, df = 3 (P = 0.90); l ² = 0% fest for overall effect: Z = 1.38 (P = 0.7) L1.6 Digit Span (Backward) igeys 2022 3.46 0.99 10 3.8 1.08 10 2.7% -0.31 [-1.20, 0.57] oo 2010 7.06 0.55 19 7.39 0.55 15 3.4% -0.29 [-1.28, 0.11] doreno 2019 5.74 2.17 64 5.69 1.83 41 5.0% -0.02 [-0.37, 0.42] ibubtoal (95% C) 126 97 15.5% -0.06 [-0.40, 0.28] teterogeneity: Tau ² = 0.04; Ch ² = 4.30, df = 3 (P = 0.23); l ² = 30% fest for overall effect: Z = 0.34 (P = 0.73) L1.7 SDMT igeys 2022 2.97.6 10.65 10 34.79 10.54 10 2.6% -0.45 [-1.35, 0.44] oo 2010 6.2.28 3.74 19 60.16 3.43 15 3.4% 0.57 [-0.12, 1.27] deterogeneity: Tau ² = 0.04; Ch ² = 4.74, df = 2 (P = 0.09); l ² = 58% fest for overall effect: Z = 0.14 (P = 0.89) L1.8 Working Memory doreno 2019 0.51 0.18 64 0.56 0.24 41 5.0% -0.08 [-0.47, 0.31] iabibotal (95% C) 76 53 7.7% 0.40 [-0.61, 0.53] teterogeneity: Tau ² = 0.14; Ch ² = 4.74, df = 2 (P = 0.09); l ² = 63% fest for overall effect: Z = 0.34; Ch ² = 5.19, df = 1 (P = 0.02); l ² = 63% res for overall effect: Z = 0.57, df = 27 (P < 0.00001); l ² = 63% res for overall effect: Z = 0.74 (P = 0.49) Test for overall effect: Z = 0.15; Ch ² = 7.23.6, df = 27 (P < 0.00001); l ² = 63% res for overall effect: Z = 0.15; Ch ² = 5.96, df = 7 (P = 0.54), l ² = 0% Test for overall effect: Z = 0.15; Ch ² = 5.96, df = 7 (P = 0.54), l ² = 0% Test for overall effect: Z = 0.15; Ch ² = 5.96, df = 7 (P = 0.54), l ² = 0% Test for overall effect: Z = 0.16; Ch = 2.59, df = 7 (P = 0.54), l ² = 0% Test for overall effect: Z = 0.16; Ch ² = 5.96, df = 7 (P = 0.54), l ² = 0% Test for overall effect: Z = 0.16; Ch = 5.96, df = 7 (P =	Heterogeneity: Tau ² =)4, df =	= 3 (P =	0.11); I			0.00 [0110, 0104]	
igeys 2022 4.98 0.97 10 5.39 1.07 10 2.7% -0.38 [-1.27, 0.50] oo 2010 8.68 2.31 19 8.68 2.05 15 3.5% 0.00 [-0.68, 0.68] oo 2012 10.4 2.64 33 11.1 2.67 31 4.4% -0.26 [-0.75, 0.23] doreno 2013 8.38 2.14 64 8.73 1.99 41 5.0% -0.07 [-0.56, 0.23] doreno 2019 8.38 2.14 64 8.73 1.99 41 5.0% -0.17 [-0.56, 0.23] doreno 2019 0.58, df = 3 (P = 0.90); l ² = 0% Test for overall effect: $Z = 1.38$ (P = 0.17) L1.6 Digit Span (Backward) igeys 2022 3.46 0.99 10 3.8 1.08 10 2.7% -0.31 [-1.20, 0.57] igeys 2022 3.46 0.99 10 3.8 1.08 10 2.7% -0.31 [-1.20, 0.57] igeys 2021 7.35 0.55 13 7.2 0.58 13 4.4% -0.26 [-0.37, 0.42] ideterogeneity: Tau ² = 0.04; Chi ² = 4.30, df = 3 (P = 0.23); l ² = 30% Test for overall effect: $Z = 0.34$ (P = 0.73) L1.7 SDMT igeys 2022 2.97.6 10.65 10 34.79 10.54 10 2.6% -0.45 [-1.35, 0.44] igeys 2022 2.97.6 10.65 10 34.79 10.54 10 2.6% -0.45 [-1.35, 0.44] igeys 2022 2.97.6 10.65 10 34.79 10.54 10 2.6% -0.45 [-1.35, 0.44] ise for overall effect: $Z = 0.34$ (P = 0.73) L1.7 SDMT igeys 2022 2.97.6 10.65 10 34.79 10.54 10 2.6% -0.45 [-1.35, 0.44] ise for overall effect: $Z = 0.34$ (P = 0.73) L1.7 SDMT igeys 2022 2.97.6 10.65 10 34.79 10.54 10 2.6% -0.45 [-1.35, 0.44] ise for overall effect: $Z = 0.34$ (P = 0.73) L1.8 Working Memory doreno 2019 0.51 0.18 6 46 0.56 0.24 41 5.0% -0.02 [-0.64, 0.15] ise tor overall effect: $Z = 0.34$ (Chi ² = 4.74, df = 2 (P = 0.09); l ² = 58% rest for overall effect: $Z = 0.34$ (Chi ² = 5.19, df = 1 (P = 0.02); l ² = 63% rest for overall effect: $Z = 0.34$ (Chi ² = 5.19, df = 1 (P = 0.02); l ² = 63% rest for overall effect: $Z = 0.74$ (P = 0.45) Total (95% CI) 766 585 100.0% 0.13 [-0.06, 0.32] -2 -1 0 -2 Favours [tDCS] Favours [control] rest for overall effect: $Z = 0.36$, df = 27 (P < 0.00001); l ² = 63% rest for overall effect: $Z = 0.36$, df = 27 (P < 0.00001); l ² = 63% rest for overall effect: $Z = 0.576$, df = 27 (P < 0.00001); l ² = 63% rest for overall effect: $Z = 0.76$, df = 7 (P = 0.54), l ² = 0% rest for overall ef			r = 0	21)						
$ \begin{array}{c} \begin{array}{c} \begin{array}{c} \begin{array}{c} \begin{array}{c} \begin{array}{c} \begin{array}{c} \begin{array}{c}$			0.97	10	5.39	1.07	10	2.7%	-0.38 [-1.27. 0.50]	
$\begin{array}{c} \text{oo} 2012 & 10.4 & 2.64 & 33 & 11.1 & 2.67 & 31 & 4.4\% & -0.26 [-0.75, 0.23] \\ \text{horeno} 2019 & 8.38 & 2.14 & 64 & 8.73 & 1.99 & 41 & 5.0\% & -0.17 [-0.56, 0.23] \\ \text{hubtotal} (95\% \text{C}) & 126 & 97 & 15.5\% & -0.19 [-0.45, 0.08] \\ \text{feetrogeneity: Tau2 = 0.00; Ch2 = 0.58, df = 3 (P = 0.30); l2 = 0\% \\ \text{fest for overall effect: Z = 1.38 (P = 0.17) \\ \textbf{L1.6 Digit Span (Backward) \\ \text{igeys 2022} & 3.46 & 0.99 & 10 & 3.8 & 1.08 & 10 & 2.7\% & -0.31 [-1.20, 0.57] \\ \text{oo} 2010 & 7.06 & 0.55 & 19 & 7.39 & 0.55 & 15 & 3.4\% & -0.59 [-1.28, 0.11] \\ \text{oo} 2012 & 7.35 & 0.55 & 33 & 7.2 & 0.58 & 31 & 4.4\% & 0.26 [-0.23, 0.75] \\ \text{doreno 2019} & 5.74 & 2.17 & 64 & 5.69 & 1.83 & 41 & 5.0\% & 0.02 [-0.37, 0.42] \\ \text{vibtotal (95\% Cf)} & 126 & 97 & 15.5\% & -0.06 [-0.40, 0.28] \\ \text{feetrogeneity: Tau2 = 0.04; Chi2 = 4.30, df = 3 (P = 0.23); l2 = 30\% \\ \text{fest for overall effect: Z = 0.34 (P = 0.73) \\ \text{L1.7 SDMT} \\ \text{igeys 2022} & 29.76 & 10.65 & 10 & 34.79 & 10.54 & 10 & 2.6\% & -0.45 [-1.35, 0.44] \\ \text{oo 2010} & 6.2.28 & 3.74 & 19 & 60.16 & 3.43 & 15 & 3.4\% & 0.57 [-0.24, 1.27] \\ \text{odereno 2019} & 0.51 & 0.18 & 64 & 0.56 & 0.24 & 41 & 5.0\% & -0.08 [-0.47, 0.31] \\ \text{isterogeneity: Tau2 = 0.14; Chi2 = 4.74, df = 2 (P = 0.09); l2 = 58\% \\ \text{Fest for overall effect: Z = 0.14 (P = 0.89) \\ \text{L1.8 Working Memory} \\ \text{doreno 2019} & 0.14 & 0.94 & 64 & 0.21 & 0.8 & 41 & 5.0\% & -0.08 [-0.47, 0.31] \\ \text{ishbotal (95\% Cf)} & 766 & 585 & 100.0\% & 0.13 [-0.06, 0.32] \\ \text{reterogeneity: Tau2 = 0.15; Chi2 = 72.36, df = 27 (P < 0.00001); l2 = 63\% \\ \text{Fest for overall effect: Z = 0.15; Chi2 = 72.36, df = 27 (P < 0.00001); l2 = 63\% \\ \text{Fest for subgroup differences: Chi2 = 5.96, df = 7 (P = 0.54), l2 = 0\% \\ \text{5} \end{array}$	Loo 2010									
Adverop 2019 8.38 2.14 64 8.73 1.99 41 5.0% -0.17 [-0.56 0.23] jubitotal (95% CI) 126 97 15.5% -0.19 [-0.45, 0.08] teterageneity: Tau ² = 0.00; Chi ² = 0.58, df = 3 (P = 0.90); l ² = 0% Test for overall effect: Z = 1.38 (P = 0.17) L1.6 Digit Span (Backward) igeys 2022 3.46 0.99 10 3.8 1.08 10 2.7% -0.31 [-1.20, 0.57] too 2010 7.06 0.55 19 7.39 0.55 15 3.4% -0.59 [-1.28, 0.11] too 2012 7.35 0.55 33 7.2 0.58 31 4.4% 0.26 [-0.37, 0.42] too 2019 5.74 2.17 64 5.69 1.03 4.1 5.0% 0.02 [-0.37, 0.42] todrero 2019 5.74 2.17 64 5.69 1.03 4.1 5.0% -0.06 [-0.40, 0.28] teterageneity: Tau ² = 0.04; Chi ² = 4.30, df = 3 (P = 0.23); l ² = 30% Test for overall effect: Z = 0.34 (P = 0.73) L1.7 SDMT igeys 2022 29.76 10.65 10 34.79 10.54 10 2.6% -0.45 [-1.35, 0.44] too 2010 62.28 3.74 19 60.16 3.43 15 3.4% 0.57 [-0.12, 1.27] doreno 2019 0.51 0.18 64 0.56 0.24 41 5.0% -0.24 [-0.64, 0.15] teterageneity: Tau ² = 0.14; Chi ² = 4.74, df = 2 (P = 0.09); l ² = 58% Test for overall effect: Z = 0.14 (P = 0.89) L1.8 Working Memory Adverno 2019 0.14 0.94 64 0.21 0.8 41 5.0% -0.08 [-0.47, 0.31] talehinejad 2017 15.86 2.32 12 13.75 1.61 12 2.8% 1.02 [0.16, 1.88] tubtotal (95% CI) 76 53 7.7% 0.40 [-0.67, 1.47] teterageneity: Tau ² = 0.15; Chi ² = 72.36, df = 27 (P < 0.00001); l ² = 63% Test for overall effect: Z = 0.14 (P = 0.46) Total (95% CI) 76 58 100.0% 0.13 [-0.06, 0.32] teterageneity: Tau ² = 0.15; Chi ² = 72.36, df = 27 (P < 0.00001); l ² = 63% Test for overall effect: Z = 0.74 (P = 0.46) Total (95% CI) 76 585 100.0% 0.13 [-0.06, 0.32] teterageneity: Tau ² = 0.15; Chi ² = 72.36, df = 27 (P < 0.00001); l ² = 63% Test for overall effect: Z = 0.74 (P = 0.46) Total (95% CI) 766 585 100.0% 0.13 [-0.06, 0.32] teterageneity: Tau ² = 0.15; Chi ² = 72.36, df = 7 (P = 0.54), l ² = 0% 5	_00 2012									
Subtotal (95% CI) 126 97 15.5% -0.19 [-0.45, 0.08] teterogeneity: Tau ² = 0.00; Ch ² = 0.58, df = 3 (P = 0.90); l ² = 0% test for overall effect: Z = 1.38 (P = 0.17) 1.1.6 Digit Span (Backward) igges 2022 3.46 0.99 10 3.8 1.08 10 2.7% -0.31 [-1.20, 0.57] to 2010 7.06 0.55 19 7.39 0.55 15 3.4% -0.59 [-1.28, 0.11] to 2012 7.35 0.55 33 7.2 0.58 31 4.4% 0.26 [-0.23, 0.75] to 2012 7.35 0.55 33 7.2 0.58 31 4.4% 0.02 [-0.37, 0.42] to 2010 5.74 2.17 64 5.69 1.83 41 5.0% 0.02 [-0.37, 0.42] teterogeneity: Tau ² = 0.04; Chi ² = 4.30, df = 3 (P = 0.23); l ² = 30% test for overall effect: Z = 0.34 (P = 0.73) 1.1.7 SDMT igges 2022 2.9.76 10.65 10 34.79 10.54 10 2.6% -0.45 [-1.35, 0.44] to 2010 62.28 3.74 19 60.16 3.43 15 3.4% 0.57 [-0.12, 1.27] doreno 2019 0.51 0.18 64 0.56 0.24 41 5.0% -0.04 [-0.61, 0.53] teterogeneity: Tau ² = 0.14; (Chi ² = 4.74, df = 2 (P = 0.09); l ² = 58% Test for overall effect: Z = 0.14 (P = 0.89) 1.1.8 Working Memory Moreno 2019 0.14 0.94 64 0.21 0.8 41 5.0% -0.08 [-0.47, 0.31] talehingad 2017 15.86 2.32 12 13.75 1.61 12 2.8% 1.02 [0.16, 1.88] totatol (95% CI) 76 53 7.7% 0.40 [-0.67, 1.47] teterogeneity: Tau ² = 0.49; Chi ² = 5.19, df = 1 (P = 0.02); l ² = 81% Test for overall effect: Z = 0.74 (P = 0.46) Total (95% CI) 766 585 100.0% 0.13 [-0.06, 0.32] teterogeneity: Tau ² = 0.15; Chi ² = 72.36, df = 27 (P < 0.00001); l ² = 63% Test for overall effect: Z = 1.30 (P = 0.19) Test for subgroup differences: Chi ² = 5.96, df = 7 (P = 0.54), l ² = 0% 5	Moreno 2019						41			
Test for overall effect: $Z = 1.38 (P = 0.17)$ L1.6 Digit Span (Backward) igeys 2022 3.46 0.99 10 3.8 1.08 10 2.7% -0.51 [-1.20, 0.57] oo 2010 7.06 0.55 19 7.39 0.55 15 3.4% -0.59 [-1.28, 0.11] oo 2012 7.35 0.55 33 7.2 0.58 31 4.4% 0.26 [-0.23, 0.75] doreno 2019 5.74 2.17 64 5.69 1.83 41 5.0% 0.02 [-0.37, 0.42] vibitotal (95% CI) 126 97 15.5% -0.06 [-0.40, 0.28] Test for overall effect: $Z = 0.34 (P = 0.73)$ L1.7 SDMT igeys 2022 29.76 10.65 10 34.79 10.54 10 2.6% -0.45 [-1.35, 0.44] oo 2010 62.28 3.74 19 60.16 3.43 15 3.4% 0.57 [-0.12, 1.27] doreno 2019 0.51 0.18 64 0.56 0.24 41 5.0% -0.24 [-0.64, 0.15] ideterogeneity: Tau ² = 0.14 (P = 0.89) L1.8 Working Memory Moreno 2019 0.14 0.94 64 0.21 0.8 41 5.0% -0.08 [-0.47, 0.31] ialehingiad 2017 15.86 2.32 12 13.75 1.61 12 2.8% 1.02 [0.16, 1.88] vibitotal (95% CI) 76 537.7% 0.40 [-0.67, 1.47] Heterogeneity: Tau ² = 0.49, Chi ² = 5.19, df = 1 (P = 0.02); l ² = 81% Test for overall effect: $Z = 0.74 (P = 0.46)$ Total (95% CI) 766 585 100.0% 0.13 [-0.06, 0.32] Heterogeneity: Tau ² = 0.15; Chi ² = 72.36, df = 27 (P < 0.00001); l ² = 63% Test for overall effect: $Z = 0.74 (P = 0.46)$ Total (95% CI) 766 585 100.0% 0.13 [-0.06, 0.32] Heterogeneity: Tau ² = 0.15; Chi ² = 72.36, df = 27 (P < 0.00001); l ² = 63% Test for overall effect: $Z = 0.74 (P = 0.46)$ Total (95% CI) 766 585 100.0% 0.13 [-0.06, 0.32] Heterogeneity: Tau ² = 0.15; Chi ² = 72.36, df = 27 (P < 0.00001); l ² = 63% Test for overall effect: $Z = 0.74 (P = 0.46)$ Total (95% CI) 766 585 100.0% 0.13 [-0.06, 0.32] Heterogeneity: Tau ² = 0.15; Chi ² = 72.36, df = 27 (P < 0.00001); l ² = 63% Test for overall effect: $Z = 0.74 (P = 0.19)$ Test for subgroup differences: Chi ² = 5.96, df = 7 (P = 0.54), l ² = 0% 5	Subtotal (95% CI)							15.5%		◆
ingeys 2022 3.46 0.99 10 3.8 1.08 10 2.7% -0.31 [-1.20, 0.57] .oo 2010 7.06 0.55 19 7.39 0.55 15 3.4% -0.59 [-1.28, 0.11] .oo 2012 7.35 0.55 33 7.2 0.58 31 4.4% 0.26 [-0.23, 0.75] .ou botoal (95% CI) 126 97 15.5% -0.06 [-0.40, 0.28] teterogeneity: Tau ² = 0.04; Chi ² = 4.30, df = 3 (P = 0.23); l ² = 30% Test for overall effect: Z = 0.34 (P = 0.73) L1.7 SDMT igeys 2022 29.76 10.65 10 34.79 10.54 10 2.6% -0.45 [-1.35, 0.44] .oo 2010 62.28 3.74 19 60.16 3.43 15 3.4% 0.57 [-0.12, 1.27] .doreno 2019 0.51 0.18 64 0.56 0.24 41 5.0% -0.24 [-0.64, 0.15] .dubtoal (95% CI) 93 66 11.0% -0.04 [-0.61, 0.53] teterogeneity: Tau ² = 0.14; Chi ² = 4.74, df = 2 (P = 0.09); l ² = 58% Test for overall effect: Z = 0.14 (P = 0.89) L1.8 Working Memory Adreno 2019 0.14 0.94 64 0.21 0.8 41 5.0% -0.08 [-0.47, 0.31] .ialehinejad 2017 15.86 2.32 12 13.75 1.61 12 2.8% 1.02 [0.16, 1.88] .ialehinejad 2017 15.86 2.32 12 13.75 1.61 12 2.8% 1.02 [0.16, 1.88] .ialehinejad 2017 15.86 2.32 12 13.75 1.61 12 2.8% 1.02 [0.16, 1.88] .ialehinejad 2017 15.86 2.32 12 13.75 1.61 12 2.8% 1.02 [0.16, 1.88] .ialehinejad 2017 15.86 2.32 12 13.75 1.61 12 2.8% 1.02 [0.16, 1.88] .ialehinejad 2017 15.86 2.32 12 13.75 1.61 12 2.8% 1.02 [0.16, 1.88] .ialehinejad 2017 15.86 2.32 12 13.75 1.61 12 2.8% 1.02 [0.16, 1.88] .ialehinejad 2017 15.86 2.32 12 13.75 1.61 12 2.8% 1.02 [0.16, 1.88] .ialehinejad 2017 15.86 2.32 12 13.75 1.61 12 2.8% 1.02 [0.16, 1.88] .ialehinejad 2017 15.86 2.32 12 13.75 1.61 12 2.8% 1.02 [0.16, 1.88] .ialehinejad 2017 5.86 2.32 12 13.75 1.61 12 2.8% 1.02 [0.16, 1.88] .ialehinejad 2017 5.86 4.02.1 0.8 41 5.0% -0.13 [-0.06, 0.32] .teterogeneity: Tau ² = 0.15; Chi ² = 72.36, df = 27 (P < 0.00001); l ² = 63% Test for overall effect: Z = 1.30 (P = 0.19) Test for overall effect: Z = 1.30 (P = 0.19) Test for subgroup differences: Chi ² = 5.96, df = 7 (P = 0.54), l ² = 0% 5					= 3 (P =	0.90); I	$^{2} = 0\%$			
$\frac{1}{5}$	1.1.6 Digit Span (Bacl	(ward)								
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	Figeys 2022									
Adverse 2019 5.74 2.17 64 5.69 1.83 41 5.0% 0.02 [-0.37, 0.42] jubtotal (95% CI) 126 97 15.5% -0.06 [-0.40, 0.28] teterogeneity: Tau ² = 0.04; Chi ² = 4.30, df = 3 (P = 0.23); l ² = 30% rest for overall effect: Z = 0.34 (P = 0.73) L1.7 SDMT rigeys 2022 29.76 10.65 10 34.79 10.54 10 2.6% -0.45 [-1.35, 0.44] i.00 2010 62.28 3.74 19 60.16 3.43 15 3.4% 0.57 [-0.12, 1.27] Adverse 2019 0.51 0.18 64 0.56 0.24 41 5.0% -0.04 [-0.64, 0.15] iabtotal (95% CI) 93 66 11.0% -0.04 [-0.61, 0.53] Heterogeneity: Tau ² = 0.14; Chi ² = 4.74, df = 2 (P = 0.09); l ² = 58% rest for overall effect: Z = 0.14 (P = 0.89) L1.8 Working Memory Adverse 2019 0.14 0.94 64 0.21 0.8 41 5.0% -0.08 [-0.47, 0.31] jabetotal (95% CI) 76 53 7.7% 0.40 [-0.67, 1.47] teterogeneity: Tau ² = 0.49; Chi ² = 5.19, df = 1 (P = 0.02); l ² = 81% rest for overall effect: Z = 0.74 (P = 0.46) Fotal (95% CI) 766 585 100.0% 0.13 [-0.06, 0.32] teterogeneity: Tau ² = 0.15; Chi ² = 72.36, df = 27 (P < 0.00001); l ² = 63% rest for overall effect: Z = 1.30 (P = 0.19) rest for subgroup differences: Chi ² = 5.96, df = 7 (P = 0.54), l ² = 0% 5	_00 2010									
Subtotal (95% CI) 126 97 15.5% -0.06 [-0.40, 0.28] deterogeneity: Tau ² = 0.04; Chi ² = 4.30, df = 3 (P = 0.23); I ² = 30% rest for overall effect: Z = 0.34 (P = 0.73) 1.1.7 SDMT riggey 2022 29.76 10.65 10 34.79 10.54 10 2.6% -0.45 [-1.35, 0.44] too 2010 62.28 3.74 19 60.16 3.43 15 3.4% 0.57 [-0.12, 1.27] doreno 2019 0.51 0.18 64 0.56 0.24 41 5.0% -0.24 [-0.64, 0.15] ibibotal (95% CI) 93 66 11.0% -0.04 [-0.61, 0.53] deterogeneity: Tau ² = 0.14; Chi ² = 4.74, df = 2 (P = 0.09); I ² = 58% rest for overall effect: Z = 0.14 (P = 0.89) 1.1.8 Working Memory Moreno 2019 0.14 0.94 64 0.21 0.8 41 5.0% -0.08 [-0.47, 0.31] ialehinejad 2017 15.86 2.32 12 13.75 1.61 12 2.8% 1.02 [0.16, 1.88] ibibotal (95% CI) 76 585 100.0% 0.13 [-0.06, 0.32] deterogeneity: Tau ² = 0.49; Chi ² = 5.19, df = 1 (P = 0.02); I ² = 81% rest for overall effect: Z = 0.74 (P = 0.46) rotal (95% CI) 766 585 100.0% 0.13 [-0.06, 0.32] deterogeneity: Tau ² = 0.15; Chi ² = 72.36, df = 27 (P < 0.00001); I ² = 63% rest for overall effect: Z = 1.30 (P = 0.19) rest for subgroup differences: Chi ² = 5.96, df = 7 (P = 0.54), I ² = 0% 5	_00 2012									
Heterogeneity: Tau ² = 0.04; Chi ² = 4.30, df = 3 (P = 0.23); l ² = 30% Test for overall effect: Z = 0.34 (P = 0.73) 1.1.7 SDMT Higeys 2022 29.76 10.65 10 34.79 10.54 10 2.6% -0.45 [-1.35, 0.44] Loo 2010 62.28 3.74 19 60.16 3.43 15 3.4% 0.57 [-0.12, 1.27] Moreno 2019 0.51 0.18 64 0.56 0.24 41 5.0% -0.24 [-0.64, 0.15] Heterogeneity: Tau ² = 0.14; Chi ² = 4.74, df = 2 (P = 0.09); l ² = 58% Test for overall effect: Z = 0.14 (P = 0.89) 1.1.8 Working Memory Moreno 2019 0.14 0.94 64 0.21 0.8 41 5.0% -0.08 [-0.47, 0.31] Halehinejad 2017 15.86 2.32 12 13.75 1.61 12 2.8% 1.02 [0.16, 1.88] Heterogeneity: Tau ² = 0.49; Chi ² = 5.19, df = 1 (P = 0.02); l ² = 81% Test for overall effect: Z = 0.74 (P = 0.46) Total (95% Cl) 76 585 100.0% 0.13 [-0.06, 0.32] Heterogeneity: Tau ² = 0.15; Chi ² = 72.36, df = 27 (P < 0.00001); l ² = 63% Test for overall effect: Z = 1.30 (P = 0.19) Test for subgroup differences: Chi ² = 5.96, df = 7 (P = 0.54), l ² = 0% 5		5.74	2.17		5.69	1.83				
The state of the		0.04; Ch	$i^2 = 4.3$		= 3 (P =	0.23); 1			0.00 [-0.40, 0.20]	T
Figers 2022 29.76 10.65 10 34.79 10.54 10 2.6% -0.45 [-1.35, 0.44] too 2010 62.28 3.74 19 60.16 3.43 15 3.4% 0.57 [-0.12, 1.27] doreno 2019 0.51 0.18 64 0.56 0.24 41 5.0% -0.24 [-0.64, 0.15] bibtotal (95% CI) 93 66 11.0% -0.04 [-0.61, 0.53] Heterogeneity: Tau ² = 0.14; Chi ² = 4.74, df = 2 (P = 0.09); l ² = 58% Test for overall effect: Z = 0.14 (P = 0.89) L1.8 Working Memory Moreno 2019 0.14 0.94 64 0.21 0.8 41 5.0% -0.08 [-0.47, 0.31] ialehinejad 2017 15.86 2.32 12 13.75 1.61 12 2.8% 1.02 [0.16, 1.88] bibtotal (95% CI) 76 53 7.7% 0.40 [-0.67, 1.47] Heterogeneity: Tau ² = 0.49; Chi ² = 5.19, df = 1 (P = 0.02); l ² = 81% Test for overall effect: Z = 0.74 (P = 0.46) Total (95% CI) 766 585 100.0% 0.13 [-0.06, 0.32] Heterogeneity: Tau ² = 0.15; Chi ² = 72.36, df = 27 (P < 0.00001); l ² = 63% Test for overall effect: Z = 1.30 (P = 0.19) Test for subgroup differences: Chi ² = 5.96, df = 7 (P = 0.54), l ² = 0% 5										
$\begin{array}{c} \begin{array}{c} \begin{array}{c} \begin{array}{c} \begin{array}{c} \begin{array}{c} \begin{array}{c} \begin{array}{c} $	L.1.7 SDMT	20.70	10.05	10	24 70	10.54	10	2.00	0451125044	
Moreno 2019 0.51 0.18 64 0.56 0.24 41 5.0% $-0.24 [-0.64, 0.15]$ Subtotal (95% CI) 93 66 11.0% $-0.04 [-0.61, 0.53]$ Heterogeneity: Tau ² = 0.14; Chi ² = 4.74, df = 2 (P = 0.09); l ² = 58% Frest for overall effect: Z = 0.14 (P = 0.89) L1.8 Working Memory Moreno 2019 0.14 0.94 64 0.21 0.8 41 5.0% $-0.08 [-0.47, 0.31]$ Lalebinejad 2017 15.86 2.32 12 13.75 1.61 12 2.8% 1.02 [0.16, 1.88] Subtotal (95% CI) 76 53 7.7% 0.40 [-0.67, 1.47] Heterogeneity: Tau ² = 0.49; Chi ² = 5.19, df = 1 (P = 0.02); l ² = 81% Frest for overall effect: Z = 0.74 (P = 0.46) Frotal (95% CI) 76 585 100.0% 0.13 [-0.06, 0.32] Heterogeneity: Tau ² = 0.15; Chi ² = 72.36, df = 27 (P < 0.00001); l ² = 63% Frest for overall effect: Z = 1.30 (P = 0.19) Fest for subgroup differences: Chi ² = 5.96, df = 7 (P = 0.54), l ² = 0% 5	J ,									
Subtotal (95% CI) 93 66 11.0% -0.04 [-0.61, 0.53] Heterogeneity: Tau ² = 0.14; Chi ² = 4.74, df = 2 (P = 0.09); l ² = 58% Test for overall effect: Z = 0.14 (P = 0.89) L1.18 Working Memory Moreno 2019 0.14 0.94 64 0.21 0.8 41 5.0% -0.08 [-0.47, 0.31] Halehinejad 2017 15.86 2.32 12 13.75 1.61 12 2.8% 1.02 [0.16, 1.88] Subtotal (95% CI) Heterogeneity: Tau ² = 0.49; Chi ² = 5.19, df = 1 (P = 0.02); l ² = 81% Total (95% CI) Total (95% CI) Total (95% CI) Total effect: Z = 0.374 (P = 0.46) Total (95% CI) Total effect: Z = 1.30 (P = 0.19) Test for overall effect: Z = 1.30 (P = 0.19) Test for subgroup differences: Chi ² = 5.96, df = 7 (P = 0.54), l ² = 0% 5										
Heterogeneity: Tau ² = 0.14; Chi ² = 4.74, df = 2 (P = 0.09); l ² = 58% Fest for overall effect: Z = 0.14 (P = 0.89) L1.8 Working Memory Moreno 2019 0.14 0.94 64 0.21 0.8 41 5.0% -0.08 [-0.47, 0.31] ialehinejad 2017 15.86 2.32 12 13.75 1.61 12 2.8% 1.02 [0.16, 1.88] iubtotal (95% Cl) 76 53 7.7% 0.40 [-0.67, 1.47] Heterogeneity: Tau ² = 0.49; Chi ² = 5.19, df = 1 (P = 0.02); l ² = 81% Fost for overall effect: Z = 0.74 (P = 0.46) Fotal (95% Cl) 766 585 100.0% 0.13 [-0.06, 0.32] Heterogeneity: Tau ² = 0.15; Chi ² = 72.36, df = 27 (P < 0.00001); l ² = 63% Fest for overall effect: Z = 1.30 (P = 0.19) Fest for subgroup differences: Chi ² = 5.96, df = 7 (P = 0.54), l ² = 0% 5	Subtotal (95% CI)	0.51	5.10		5.50	5.67				-
The set for overall effect: $Z = 0.14$ (P = 0.89) L1.8 Working Memory Moreno 2019 0.14 0.94 64 0.21 0.8 41 5.0% -0.08 [-0.47, 0.31] Stalehinejad 2017 15.86 2.32 12 13.75 1.61 12 2.8% 1.02 [0.16, 1.88] Stalehinejad 2017 15.86 2.32 12 13.75 1.61 12 2.8% 0.40 [-0.67, 1.47] Heterogeneity: Tau ² = 0.49; Chl ² = 5.19, df = 1 (P = 0.02); l ² = 81% Treat for overall effect: Z = 0.74 (P = 0.46) Total (95% Cl) 766 585 100.0% 0.13 [-0.06, 0.32] Heterogeneity: Tau ² = 0.15; Chl ² = 72.36, df = 27 (P < 0.00001); l ² = 63% Treat for overall effect: Z = 1.30 (P = 0.19) Test for subgroup differences: Chl ² = 5.96, df = 7 (P = 0.54), l ² = 0% 5		0.14; Ch	$i^2 = 4.7$	4, df =	= 2 (P =	0.09); 1	² = 58%		A CONTRACTOR OF	1
Moreno 2019 0.14 0.94 64 0.21 0.8 41 5.0% -0.08 [-0.47, 0.31] ialehinejad 2017 15.86 2.32 12 13.75 1.61 12 2.8% 1.02 [0.16, 1.88] isubtotal (95% Cl) 76 53 7.7% 0.40 [-0.67, 1.47] Heterogeneity: Tau ² = 0.49; Chi ² = 5.19, df = 1 (P = 0.02); l ² = 81% Fotal (95% Cl) 766 585 100.0% 0.13 [-0.06, 0.32] Heterogeneity: Tau ² = 0.15; Chi ² = 72.36, df = 27 (P < 0.00001); l ² = 63% Frest for overall effect: Z = 1.30 (P = 0.19) Fest for subgroup differences: Chi ² = 5.96, df = 7 (P = 0.54), l ² = 0% 5										
ialehinejad 2017 15.86 2.32 12 13.75 1.61 12 2.8% 1.02 [0.16, 1.88] isubtotal (95% CI) 76 53 7.7% 0.40 [-0.67, 1.47] Heterogeneity: Tau ² = 0.49; Chi ² = 5.19, df = 1 (P = 0.02); l ² = 81% 0.40 [-0.67, 1.47] Fost for overall effect: Z = 0.74 (P = 0.46) 766 585 100.0% 0.13 [-0.06, 0.32] Heterogeneity: Tau ² = 0.15; Chi ² = 72.36, df = 27 (P < 0.00001); l ² = 63% 0.13 [-0.06, 0.32] -2 -1 0 1 2 Fest for overall effect: Z = 1.30 (P = 0.19) 5 5 1.02 [0.13] [-0.06, 0.32] -2 -1 0 1 2 Fest for subgroup differences: Chi ² = 5.96, df = 7 (P = 0.54), l ² = 0% 5 <td< td=""><td></td><td>· · · · · · · · · · · · · · · · · · ·</td><td>0.04</td><td>64</td><td>0.21</td><td>0.0</td><td>41</td><td>E 00/</td><td>0.08[0.47.0.31]</td><td></td></td<>		· · · · · · · · · · · · · · · · · · ·	0.04	64	0.21	0.0	41	E 00/	0.08[0.47.0.31]	
Subtotal (95% Cl) 76 53 7.7% 0.40 [-0.67, 1.47] Heterogeneity: Tau ² = 0.49; Chi ² = 5.19, df = 1 (P = 0.02); I ² = 81% 0.40 [-0.67, 1.47] Fest for overall effect: Z = 0.74 (P = 0.46) 0.13 [-0.06, 0.32] Fotal (95% Cl) 766 585 100.0% 0.13 [-0.06, 0.32] Heterogeneity: Tau ² = 0.15; Chi ² = 72.36, df = 27 (P < 0.00001); I ² = 63% 0.13 [-0.06, 0.32] -2 Fest for overall effect: Z = 1.30 (P = 0.19) Favours [control] Favours [tDCS] Favours [control] Fest for subgroup differences: Chi ² = 5.96, df = 7 (P = 0.54), I ² = 0% 5 5										
Heterogeneity: Tau ² = 0.49; Chi ² = 5.19, df = 1 (P = 0.02); l ² = 81% Fost for overall effect: Z = 0.74 (P = 0.46) Fotal (95% Cl) 766 585 100.0% 0.13 [-0.06, 0.32] Heterogeneity: Tau ² = 0.15; Chi ² = 72.36, df = 27 (P < 0.00001); l ² = 63% Test for overall effect: Z = 1.30 (P = 0.19) Fest for subgroup differences: Chi ² = 5.96, df = 7 (P = 0.54), l ² = 0% 5	Subtotal (95% CI)	13.00	2.52		13.73	1.01				
Test for overall effect: Z = 0.74 (P = 0.46) Fotal (95% CI) 766 585 100.0% 0.13 [-0.06, 0.32] Heterogeneity: Tau ² = 0.15; Chi ² = 72.36, df = 27 (P < 0.00001); l ² = 63% 0.13 [-0.06, 0.32] -2 -1 0 1 2 rest for overall effect: Z = 1.30 (P = 0.19) rest for subgroup differences: Chi ² = 5.96, df = 7 (P = 0.54), l ² = 0% $Favours [tDCS] Favours [control] 5 $		0.49 [.] Ch	$i^2 = 5$		= 1 (P =	0.02): 1				
Heterogeneity: Tau ² = 0.15; Chi ² = 72.36, df = 27 (P < 0.00001); I ² = 63% Test for overall effect: Z = 1.30 (P = 0.19) Test for subgroup differences: Chi ² = 5.96, df = 7 (P = 0.54), I ² = 0% 5					- (, -		01/	50		
Test for overall effect: Z = 1.30 (P = 0.19) -2 -1 0 1 2 Test for subgroup differences: Chi ² = 5.96, df = 7 (P = 0.54), l ² = 0% Favours [tDCS] Favours [control] 5	Fotal (95% CI)	0.15.05	i ² - 70		- 27 (5	< 0.00			0.13 [-0.06, 0.32]	
Test for subgroup differences: $Chi^2 = 5.96$, $df = 7$ (P = 0.54), $I^2 = 0\%$					= 27 (P	< 0.00	001); [*	= 03%		-2 -1 0 1 2
5					f = 7 (P	= 0.54	$ ^2 = 0$	1%		Favours [tDCS] Favours [control]
	and and and and					5.5 1)		10		
tive function measures. TMT, Trail Making Test; SDMT, Symbol Digit Modalities Test.	5		·· ·	A a l ·:	Tart		un-l-	Distant	delities Tot	

	tDC	S	Contr	rol		Odds Ratio		Odds Ratio			
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI		M-H, Random, 95% CI			
Kumar 2020	14	18	9	15	34.4%	2.33 [0.51, 10.64]					
Loo 2012	30	33	29	31	22.9%	0.69 [0.11, 4.43]					
Nord 2019	6	20	6	19	42.8%	0.93 [0.24, 3.62]					
Total (95% CI)		71		65	100.0%	1.19 [0.49, 2.90]					
Total events	50		44								
Heterogeneity: Tau ²	= 0.00; Cł	$ni^2 = 1.$	21, df =	2 (P =	0.54); l ² :	= 0%	0.05				
Test for overall effec	t: Z = 0.38	B(P = 0)).70)				0.05	0.2 1 5 Favours [tDCS] Favours [con	20 itrol]		
GURE 6											
dverse events.											

The positive impact of this combination may arise from tDCS acutely enhancing attention or executive function during cognitive tasks, leading to improved learning outcomes (Kumar et al., 2020). Alternatively, tDCS treatment administered after cognitive tasks may contribute to memory consolidation (Vorobiova et al., 2019; Sandrini et al., 2019). Thus, future studies should explore both immediate and sustained effects of combining tDCS with cognitive stimulation to enhance global cognition in older patients with MDD (Oken, 2008; Fonteneau et al., 2019; Calamia et al., 2012).

Moreover, we performed subgroup analyses to investigate the impact of tDCS on eight cognitive function outcomes, and identified there was no beneficial effect of a treatment course of active tDCS compared to sham treatment across the examined dimension-specific cognitive measures. While a single tDCS treatment in patients with depression has been demonstrated to produce acute cognitive enhancement, our results indicated that there is no cumulative or longterm improvement effect when these courses are repeated. Additionally, the absence of differential cognitive effects may also be attributed to the possible lack of sensitivity of the tests that were included in these studies to detect subtle differences in cognition, particularly in attention states previously associated with tDCS (Gladwin et al., 2012). Another potential explanation could be the occurrence of type 2 error due to the small sample size.

Our analysis of tDCS revealed that it did not trigger any adverse side effects in patients with major depression, indicating its safety as an antidepressant treatment (Bares et al., 2019; Razza et al., 2023). Nonetheless, further research is needed, as some findings suggest enhanced practical gains in cognitive performance after tDCS. Additionally, we observed an enhancement in verbal memory in tDCS responders, and this finding also warrant confirmation in further studies. Future clinical trials employing tDCS should try to determine the optimal stimulus parameters, dose requirements, and predictors of a favorable treatment response, thereby enhancing its therapeutic potential.

As study strengths, this is the largest meta-analysis evaluating the efficacy of tDCS in depression to date. We implemented a rigorous assessment process for study eligibility and quality, ensuring that only high-standard research was included in our analysis. Furthermore, we utilized additional meta-analytical techniques to reinforce the robustness of our findings. Specifically, we conducted a thorough assessment of publication bias, which helped us to identify and account for any potential biases in the literature. Additionally, we employed both randomeffects and fixed-effects models, providing a comprehensive and nuanced understanding of the data. These methodological strengths significantly enhance the credibility and reliability of our results, offering valuable insights into the potential of tDCS as a treatment for depression. Undoubtedly, our study also had some limitations. First, due to the limited studies on tDCS treatment for cognitive function in depressed patients, the sample size is relatively small. Therefore, although the meta-analysis was used to further expand the sample size in this study, it still needs to be enriched; Secondly, as the tDCS effects are shown to be more effective in individuals with more severe cognitive deficits, thereby, this confounding factor needs to be considered for future inclusion in the meta-analysis (Hill et al., 2016). Thirdly, we excluded RCTs that did not assess cognitive functions, potentially introducing bias into the sample. To address this limitation and provide a more comprehensive understanding of tDCS's effects on MDD, future studies should incorporate a wider range of RCTs, including those that investigate both the antidepressant and cognitive effects of tDCS. Additionally, larger-scale, well-designed RCTs are needed to validate our findings and further explore optimal treatment parameters, dosage requirements, and predictors of response to tDCS in MDD patients.

Data availability statement

The original contributions presented in the study are included in the article/supplementary material, further inquiries can be directed to the corresponding author.

Author contributions

JW: Formal analysis, Investigation, Writing – original draft. XY: Investigation, Validation, Writing – review & editing. YJ: Investigation, Methodology, Validation, Writing – original draft. HL: Conceptualization, Funding acquisition, Supervision, Writing – review & editing.

Funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This work was supported by the National Natural Science Foundation of China (82101610), China Postdoctoral Science Foundation (2023M732156), and Doctoral Research Initiation Fund Project (XD2103).

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

Aust, S., Brakemeier, E. L., Spies, J., Herrera-Melendez, A. L., Kaiser, T., Fallgatter, A., et al. (2022). Efficacy of augmentation of cognitive behavioral therapy with transcranial direct current stimulation for depression: a randomized clinical trial. *JAMA Psychiatry* 79, 528–537. doi: 10.1001/jamapsychiatry.2022.0696

Bares, M., Brunovsky, M., Stopkova, P., Hejzlar, M., and Novak, T. (2019). Transcranial direct-current stimulation (tDCS) versus venlafaxine ER in the treatment of depression: a randomized, double-blind, single-center study with open-label, followup. *Neuropsychiatr. Dis. Treat.* 15, 3003–3014. doi: 10.2147/NDT.S226577

Bennabi, D., Nicolier, M., Monnin, J., Tio, G., Pazart, L., Vandel, P., et al. (2015). Pilot study of feasibility of the effect of treatment with tDCS in patients suffering from treatment-resistant depression treated with escitalopram. *Clin. Neurophysiol.* 126, 1185–1189. doi: 10.1016/j.clinph.2014.09.026

Boggio, P. S., Khoury, L. P., Martins, D. C., Martins, O. E., de Macedo, E. C., Fregni, F., et al. (2009). Temporal cortex direct current stimulation enhances performance on a visual recognition memory task in Alzheimer disease. *J. Neurol. Neurosurg. Psychiatr.* 80, 444–447. doi: 10.1136/jnnp.2007.141853

Brunoni, A. R., Moffa, A. H., Fregni, F., Palm, U., Padberg, F., Blumberger, D. M., et al. (2016). Transcranial direct current stimulation for acute major depressive episodes: meta-analysis of individual patient data. *Br. J. Psychiatry* 208, 522–531. doi: 10.1192/bjp.bp.115.164715

Brunoni, A. R., Moffa, A. H., Sampaio-Junior, B., Borrione, L., Moreno, M. L., Fernandes, R. A., et al. (2017). Trial of electrical direct-current therapy versus escitalopram for depression. *N. Engl. J. Med.* 376, 2523–2533. doi: 10.1056/NEJMoa1612999

Calamia, M., Markon, K., and Tranel, D. (2012). Scoring higher the second time around: meta-analyses of practice effects in neuropsychological assessment. *Clin. Neuropsychol.* 26, 543–570. doi: 10.1080/13854046.2012.680913

Chen, J., Wang, Z., Chen, Q., Fu, Y., and Zheng, K. (2022). Transcranial direct current stimulation enhances cognitive function in patients with mild cognitive impairment and early/mid alzheimer's disease: a systematic review and meta-analysis. *Brain Sci.* 12:562. doi: 10.3390/brainsci12050562

Chopra, K., and Arora, V. (2014). An intricate relationship between pain and depression: clinical correlates, coactivation factors and therapeutic targets. *Exp. Opin. Ther. Targets* 18, 159–176. doi: 10.1517/14728222.2014.855720

Culpepper, L., Lam, R. W., and McIntyre, R. S. (2017). Cognitive impairment in patients with depression: awareness, assessment, and management. *J. Clin. Psychiatry* 78, 1383–1394. doi: 10.4088/JCP.tk16043ah5c

DiMatteo, M. R., Lepper, H. S., and Croghan, T. W. (2000). Depression is a risk factor for noncompliance with medical treatment: meta-analysis of the effects of anxiety and depression on patient adherence. *Arch. Intern. Med.* 160, 2101–2107. doi: 10.1001/archinte.160.14.2101

Douglas, K. M., Groves, S., Crowe, M. T., Inder, M. L., Jordan, J., Carlyle, D., et al. (2022). A randomised controlled trial of psychotherapy and cognitive remediation to target cognition in mood disorders. *Acta Psychiatr. Scand.* 145, 278–292. doi: 10.1111/acps.13387

Egede, L. E. (2007). Major depression in individuals with chronic medical disorders: prevalence, correlates and association with health resource utilization, lost productivity and functional disability. *Gen. Hosp. Psychiatry* 29, 409–416. doi: 10.1016/j.genhosppsych.2007.06.002

Figeys, M., Villarey, S., Leung, A. W. S., Raso, J., Buchan, S., Kammerer, H., et al. (2022). tDCS over the left prefrontal Cortex improves mental flexibility and inhibition

in geriatric inpatients with symptoms of depression or anxiety: a pilot randomized controlled trial. *Front. Rehabil. Sci.* 3:997531. doi: 10.3389/fresc.2022.997531

Fonteneau, C., Mondino, M., Arns, M., Baeken, C., Bikson, M., Brunoni, A. R., et al. (2019). Sham tDCS: a hidden source of variability? Reflections for further blinded, controlled trials. *Brain Stimul.* 12, 668–673. doi: 10.1016/j.brs.2018.12.977

Gladwin, T. E., den Uyl, T. E., Fregni, F. F., and Wiers, R. W. (2012). Enhancement of selective attention by tDCS: interaction with interference in a Sternberg task. *Neurosci. Lett.* 512, 33–37. doi: 10.1016/j.neulet.2012.01.056

Gogler, N., Willacker, L., Funk, J., Strube, W., Langgartner, S., Napiorkowski, N., et al. (2017). Single-session transcranial direct current stimulation induces enduring enhancement of visual processing speed in patients with major depression. *Eur. Arch. Psychiatry Clin. Neurosci.* 267, 671–686. doi: 10.1007/s00406-016-0761-y

Hale, J. M., Schneider, D. C., Mehta, N. K., and Myrskyla, M. (2020). Cognitive impairment in the U.S.: Lifetime risk, age at onset, and years impaired. *SSM Popul. Health* 11:100577. doi: 10.1016/j.ssmph.2020.100577

Higgins, J. P., Altman, D. G., Gotzsche, P. C., Juni, P., Moher, D., Oxman, A. D., et al. (2011). The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. *BMJ* 343:d5928. doi: 10.1136/bmj.d5928

Hill, A. T., Fitzgerald, P. B., and Hoy, K. E. (2016). Effects of anodal transcranial direct current stimulation on working memory: a systematic review and meta-analysis of findings from healthy and neuropsychiatric populations. *Brain Stimul.* 9, 197–208. doi: 10.1016/j.brs.2015.10.006

Ismail, Z., Elbayoumi, H., Fischer, C. E., Hogan, D. B., Millikin, C. P., Schweizer, T., et al. (2017). Prevalence of depression in patients with mild cognitive impairment: a systematic review and meta-analysis. *JAMA Psychiatry* 74, 58–67. doi: 10.1001/jamapsychiatry.2016.3162

Keefe, R. S., McClintock, S. M., Roth, R. M., Doraiswamy, P. M., Tiger, S., Madhoo, M., et al. (2014). Cognitive effects of pharmacotherapy for major depressive disorder: a systematic review. *J. Clin. Psychiatry* 75, 864–876. doi: 10.4088/JCP.13r08609

Kroenke, K., Wu, J., Bair, M. J., Krebs, E. E., Damush, T. M., Tu, W., et al. (2011). Reciprocal relationship between pain and depression: a 12-month longitudinal analysis in primary care. *J. Pain* 12, 964–973. doi: 10.1016/j.jpain.2011.03.003

Kumar, S., Batist, J., Ghazala, Z., Zomorrodi, R. M., Brooks, H., Goodman, M., et al. (2020). Effects of bilateral transcranial direct current stimulation on working memory and global cognition in older patients with remitted major depression: a pilot randomized clinical trial. *Int. J. Geriatr. Psychiatry* 35, 1233–1242. doi: 10.1002/gps.5361

Lefaucheur, J. P., Antal, A., Ayache, S. S., Benninger, D. H., Brunelin, J., Cogiamanian, F., et al. (2017). Evidence-based guidelines on the therapeutic use of transcranial direct current stimulation (tDCS). *Clin. Neurophysiol.* 128, 56–92. doi: 10.1016/j.clinph.2016.10.087

Loo, C. K., Alonzo, A., Martin, D., Mitchell, P. B., Galvez, V., Sachdev, P., et al. (2012). Transcranial direct current stimulation for depression: 3-week, randomised, sham-controlled trial. *Br. J. Psychiatry* 200, 52–59. doi: 10.1192/bjp.bp.111.097634

Loo, C. K., Husain, M. M., McDonald, W. M., Aaronson, S., O'Reardon, J. P., Alonzo, A., et al. (2018). International randomized-controlled trial of transcranial Direct Current Stimulation in depression. *Brain Stimul.* 11, 125–133. doi: 10.1016/j.brs.2017.10.011

Loo, C. K., Sachdev, P., Martin, D., Pigot, M., Alonzo, A., Malhi, G. S., et al. (2010). A double-blind, sham-controlled trial of transcranial direct current

stimulation for the treatment of depression. Int. J. Neuropsychopharmacol. 13, 61–69. doi: 10.1017/S1461145709990411

Martin, D. M., Moffa, A., Nikolin, S., Bennabi, D., Brunoni, A. R., Flannery, W., et al. (2018). Cognitive effects of transcranial direct current stimulation treatment in patients with major depressive disorder: an individual patient data metaanalysis of randomised, sham-controlled trials. *Neurosci. Biobehav. Rev.* 90, 137–145. doi: 10.1016/j.neubiorev.2018.04.008

Mayur, P., Howari, R., Byth, K., and Vannitamby, R. (2018). Concomitant transcranial direct current stimulation with ultrabrief electroconvulsive therapy: a 2-week double-blind randomized sham-controlled trial. *J. ECT* 34, 291–295. doi: 10.1097/YCT.00000000000479

Miguel, C., Karyotaki, E., Ciharova, M., Cristea, I. A., Penninx, B., Cuijpers, P., et al. (2023). Psychotherapy for comorbid depression and somatic disorders: a systematic review and meta-analysis. *Psychol. Med.* 53, 2503–2513. doi: 10.1017/S0033291721004414

Miller, L. R., and Cano, A. (2009). Comorbid chronic pain and depression: who is at risk? J. Pain 10, 619–627. doi: 10.1016/j.jpain.2008.12.007

Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., and Group, P. (2009). Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *PLoS Med.* 6:e1000097. doi: 10.1371/journal.pmed.1000097

Moreno, M. L., Goerigk, S. A., Bertola, L., Suemoto, C. K., Razza, L. B., Moffa, A. H., et al. (2020). Cognitive changes after tDCS and escitalopram treatment in major depressive disorder: results from the placebo-controlled ELECT-TDCS trial. *J. Affect. Disord.* 263, 344–352. doi: 10.1016/j.jad.2019.12.009

Moreno, M. L., Vanderhasselt, M. A., Carvalho, A. F., Moffa, A. H., Lotufo, P. A., Bensenor, I. M., et al. (2015). Effects of acute transcranial direct current stimulation in hot and cold working memory tasks in healthy and depressed subjects. *Neurosci. Lett.* 591, 126–131. doi: 10.1016/j.neulet.2015.02.036

Nejati, V., Majidinezhad, M., and Nitsche, M. (2022). The role of the dorsolateral and ventromedial prefrontal cortex in emotion regulation in females with major depressive disorder (MDD): a tDCS study. *J. Psychiatr. Res.* 148, 149–158. doi: 10.1016/j.jpsychires.2022.01.030

Nelson, J. T., McKinley, R. A., Golob, E. J., Warm, J. S., and Parasuraman, R. (2014). Enhancing vigilance in operators with prefrontal cortex transcranial direct current stimulation (tDCS). *Neuroimage*. 85(Pt 3), 909–917. doi: 10.1016/j.neuroimage.2012.11.061

Nord, C. L., Halahakoon, D. C., Limbachya, T., Charpentier, C., Lally, N., Walsh, V., et al. (2019). Neural predictors of treatment response to brain stimulation and psychological therapy in depression: a double-blind randomized controlled trial. *Neuropsychopharmacology* 44, 1613–1622. doi: 10.1038/s41386-019-0401-0

Oken, B. S. (2008). Placebo effects: clinical aspects and neurobiology. *Brain* 131(Pt 11), 2812–2823. doi: 10.1093/brain/awn116

Palm, U., Schiller, C., Fintescu, Z., Obermeier, M., Keeser, D., Reisinger, E., et al. (2012). Transcranial direct current stimulation in treatment resistant depression: a randomized double-blind, placebo-controlled study. *Brain Stimul.* 5, 242–251. doi: 10.1016/j.brs.2011.08.005

Poppe, A., Bais, L., van Duin, D., Curcic-Blake, B., Pijnenborg, G. H. M., van der Meer, L., et al. (2021). Improving cognition in severe mental illness by combining cognitive remediation and transcranial direct current stimulation: study protocol for a pragmatic randomized controlled pilot trial (HEADDSET). *Trials* 22:275. doi: 10.1186/s13063-021-05230-8

Razza, L. B., Luethi, M. S., Zanao, T., De Smet, S., Buchpiguel, C., Busatto, G., et al. (2023). Transcranial direct current stimulation versus intermittent theta-burst stimulation for the improvement of working memory performance. *Int. J. Clin. Health Psychol.* 23:100334. doi: 10.1016/j.ijchp.2022.100334

Rock, P. L., Roiser, J. P., Riedel, W. J., and Blackwell, A. D. (2014). Cognitive impairment in depression: a systematic review and meta-analysis. *Psychol. Med.* 44, 2029–2040. doi: 10.1017/S0033291713002535

Salehinejad, M. A., Ghanavai, E., Rostami, R., and Nejati, V. (2017). Cognitive control dysfunction in emotion dysregulation and psychopathology of major depression (MD): evidence from transcranial brain stimulation of the dorsolateral prefrontal cortex (DLPFC). *J. Affect. Disord.* 210, 241–248. doi: 10.1016/j.jad.2016.12.036

Salehinejad, M. A., Rostami, R., and Ghanavati, E. (2015). Transcranial direct current stimulation of dorsolateral prefrontal cortex in major depression: improving visual working memory, reducing depressive symptoms. *NeuroRegulation* 2, 37–49. doi: 10.15540/nr.2.1.37

Sandrini, M., Manenti, R., Gobbi, E., Rusich, D., Bartl, G., Cotelli, M., et al. (2019). Transcranial direct current stimulation applied after encoding facilitates episodic memory consolidation in older adults. *Neurobiol. Learn. Mem.* 163:107037. doi: 10.1016/j.nlm.2019.107037

Simko, P., Pupikova, M., Gajdos, M., and Rektorova, I. (2021). Cognitive aftereffects of acute tDCS coupled with cognitive training: an fMRI study in healthy seniors. *Neural Plast.* 2021:6664479. doi: 10.1155/2021/6664479

Vorobiova, A. N., Pozdniakov, I., and Feurra, M. (2019). Transcranial direct current stimulation effects on memory consolidation: timing matters. *eNeuro*. 6:ENEURO.0481-18.2019. doi: 10.1523/ENEURO.0481-18.2019

Wagner, S., Doering, B., Helmreich, I., Lieb, K., and Tadic, A. (2012). A meta-analysis of executive dysfunctions in unipolar major depressive disorder without psychotic symptoms and their changes during antidepressant treatment. *Acta Psychiatr. Scand.* 125, 281–292. doi: 10.1111/j.1600-0447.2011. 01762.x

Wang, H., Wang, K., Xue, Q., Peng, M., Yin, L., Gu, X., et al. (2022). Transcranial alternating current stimulation for treating depression: a randomized controlled trial. *Brain* 145, 83–91. doi: 10.1093/brain/awab252

Williams, L. M. (2017). Defining biotypes for depression and anxiety based on large-scale circuit dysfunction: a theoretical review of the evidence and future directions for clinical translation. *Depress. Anxiety* 34, 9–24. doi: 10.1002/da. 22556

Wolkenstein, L., and Plewnia, C. (2013). Amelioration of cognitive control in depression by transcranial direct current stimulation. *Biol. Psychiatry* 73, 646–651. doi: 10.1016/j.biopsych.2012.10.010